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SUMMARY
Trace element biochemistry following a multielement intravenous 
infusion in man was studied. A new trace-element additive mixture 
was prepared by Kabi-Vitrum, Sweden (code 4854). to meet the 
requirements of moderately ill patients. This mixture provided 
a daily supply of Fe 20 |jmol (1.12 mg); Zn 100 jumol (6.54 mg);
Cu 20 jjmol (1.27 mg); Mn 15 pmol (0.82 mg); Cr 0.4 jumol (20.8 
pg); Se 0.4 pmol (31.58 ug); Mo 0.2 pmol (19.19 ug); I 1.0 pmol 
(0.13 mg); F 50 pmol (0.95 mg). To evaluate the efficacy of 
this mixture in meeting the trace-element requirements in patients, 
three different studies were undertaken. Serum and urine samples 
were collected with precautions to avoid contamination. Levels of 
zinc, copper, manganese, chromium and selenium, in serum and 
urine were determined by proven atomic absorption techniques.
Results were compared statistically within and between the 
groups and to appropriate reference values. This thesis deals 
with the determination of zinc, copper, manganese, chromium 
and selenium in serum and urine. Methods for Mo, I and F were 
not readily available. Studies were as follows:
Crystalloid Study: In this study, twenty patients undergoing
elective abdominal surgery were randomly allocated into two 
groups. Group A received saline and glucose (5%) only for 
four post-operative days. Group B received an additional daily 
infusion of trace-element mixture (code 4854). , In Group A 
serum zinc fell sharply, but returned to normal by day 
five. Serum copper, manganese, chromium and selenium were
unchanged and urinary excretions did not alter. In Group B, 
serum zinc followed the same pattern as Group A, but serum copper 
and selenium were mostly unaffected. Serum and urinary chromium 
and manganese were markedly increased during infusion, whereas
10
urinary zinc, copper and selenium were not significantly increased. 
Surgical I.V.N.: In this study, sixteen patients undergoing
elective surgery were studied for more than seven days. They 
received 14 g N and 3000 KCal/day (2000 KCal as glucose, and
1000 KCal as Intralipid) and trace element additive mixture. 
These patients were divided into two groups. Group A as anabolic
patients with urine N less than 12 g/day. Group B as catabolic
patients with urine N greater than 14 g/day. In both groups, 
serum values of zinc, copper and selenium remained normal, while 
manganese and chromium increased. Urinary excretion of copper 
was unaffected, while that of zinc, manganese, chromium and 
selenium was increased.
Medical I.V.N.: Four patients were studied for more than fourteen 
days. The infusion regimen was similar to that used in surgical 
IVN. Serum zinc and copper were maintained during infusion 
and manganese and chromium were elevated, while selenium was 
at the lower level of normal range. Urinary excretion was 
increased for chromium, zinc and manganese, while copper and 
selenium were unaffected.
The supplement of zinc and copper was sufficient to correct 
any pre-existing abnormality and to maintain most of the patients. 
However, for patients with excessive intestinal fluid loss higher 
amounts may be desirable. The provision of manganese and chromium 
may have been excessive, only half of the amount provided may 
be enough for most patients.
No clinical or biochemical abnormality suggestive of de­
ficiency or toxicity for any of the infused elements was found.
CHAPTER 1
INTRODUCTION
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INTRODUCTION
The human body mostly consists of water, protein, carbohydrate 
and fat. Inorganic elements in tissue could be classified as 
major elements such as the electrolytes (Na, K, Cl) or minerals 
such as (Ca, Mg, P). These are present at levels of several 
hundred parts per million, that is milligrams per litre. There 
are also about fifty inorganic elements present at lower con­
centrations which have been described as "trace elements", since 
by earlier analytical techniques their levels could not be reliably 
determined. Bioscientists define trace elements as a group 
of elements that occur in animal and plant tissues at concen­
trations ranging from several hundred pg/g to barely detectable 
levels of the order of pico gram per gram ( Pg/%). By widely 
accepted custom, elements that do not exceed the tissue concen­
trations of iron are included in this category:
An element is defined as "essential element" if:
A) The amount present in the tissue of a particular species 
is constant.
B) Removal from diet produces reproducible abnormalities.
C) Addition back to diet of that element alone, reverses 
the changes.
D) Clinical reversible changes are accompanied by biochemical 
effects.
Major Elements and Electrolytes
These are the eleven elements present in substantial amounts 
forming 99.5% of tissue. They are carbon, hydrogen, Oxygen, 
nitrogen, sulphur, calcium, magnesium, phosphorous, sodium,
potassium and chloride.
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1.2 Essential Trace Elements
There are fourteen trace elements which are present in the human 
body, at concentrations less than 50 mg/kg of tissue and in 
body fluids at less than 1 mg/litre (in micromolar or nanomolar 
concentrations). Less than half of these essential elements 
are of recognised importance in human medicine even although 
their biological requirement has been demonstrated in one or 
more animal species (Underwood 1979). The elements are F, 
Cr, Fe, Co, Cu, I, Mn, Mo, Ni, Se, Si, V, Sn, Zn. Exclusion 
of each of these trace elements from the diet of experimental 
animals produces a reduction in growth, failure of normal develop­
ment, or other adverse effects on health, which are reversible 
uniquely upon re-introduction of that element to the diet .
The first discovery of an essential trace metal (Iron) 
was in the 17th century. Two centuries later, iodine was also 
added in this category, but since 1970 with the development 
of analytical techniques such as polarography, neutron activ­
ation and spectrophotometry, more and more essential trace elements 
have been discovered. Table 1 gives a list of essential trace 
elements and their year of discovery. The experience of the 
past two decades suggests that the number of trace elements 
of biological interest, may continue to increase in the future.
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TABLE 1
Discovery of Trace Elements
Element
Iron (Fe) 
Iodine (I)
Year
17th century
1850-19th
century
Copper (Cu) 1928 
Manganese (Mn) 1931
Zinc (Zn)
Cobalt (Co)
Molybdenum
(Mo)
1934
1935 
1953
Selenium (Se) 1959
Chromium (Cr) 1959
Tin (Sn) 1970
Vanadium (V) 1971
Fluoride (F) 1971
Silicon (Si) 1972
Nickel (Ni) 1974
Effect of deficiency
Anaemia
Goitre
Anaemia and bone problems
Growth impairment, reproductive 
disorders, neuromuscular diseases
Growth defect, skin disorders for both 
man and animals
Growth and anaemia
Essential for animal growth
Growth and fertility in animals
Growth, reduce life span, disturbances 
of glucose, lipid and protein metabolism
Animal growth
Animal growth
Dentalcaries in animal and man 
Connective tissue 
Animals only
Other elements such as Arsenic (As), Cadmium (Cd) and Lead 
(Pb), are considered as border-line cases.
Many of these elements are of fundamental biochemical importance. 
For example, zinc is a key factor in nucleic acid and protein syn­
thesis, selenium is a part of the cellular anti-oxidant defence.
The increased sensitivity and specificity of modern analytical 
methods, such as atomic absorption spectrophotometry when carefully 
applied, can reliably determine most of the essential elements
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at the levels normally occurring in human tissue and body fluids.
The ultimate objective of trace element research is the under­
standing of the mode of action of an element at the molecular and 
organ level, of its metabolism and requirement by different species 
and of the consequences of inadequate intake. This knowledge serves 
as the basis for assessment of the nutritional status of individuals 
and population groups and if necessary, as justification for inter­
vention prgrammes to assure adequate intakes.
Patients with massive injuries, after extensive surgical pro­
cedures, or critically ill patients, can be stabilised and maintained 
for long periods by the use of supplementary nutrition such as 
intravenous feeding. In giving the parenteral nutrition regimen, 
most consideration is usually given to the volume of fluid which 
should be infused, the amount of amino acid nitrogen necessary 
and the amount and chemical form of energy substrate. Although 
these are the major nutrients, it is important to remember that 
the objective of complete parenteral nutrition is to provide by 
the intravenous route, all nutrients in the same amount and chemical 
form as would normally be absorbed via the gastro-intestinal tract 
from an adequate oral diet. Thus, an appropriate infusion of 
major and minor elements in their appropriate chemical form, together 
with all vitamins, should ideally be given.
To have complete intravenous nutrition theoretically, fourteen 
essential elements should be added to the regimen. But this is 
not practicable for three reasons :
A) The amounts and chemical form in normal diet are not known for
all trace elements, especially those at the lowest level.
(Silicon, Nickel, Arsenic, Vanadium, Molybdenum).
B) The amount and chemical form needed intravenously is unknown
since the various factors in regulating normal gastro-intestinal
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uptake are far from understood.
C) The altered intravenous requirement of various categories of 
ill patients are not known.
With those uncertainties, it is considered wise to only propose 
addition of the better established elements of known metabolic 
importance. Elements in this category are zinc, copper, iron, 
chromium, selenium, manganese, molydenum, fluoride and iodide.
The elements in this group can be considered in three main cate­
gories :
1) Those where clinical deficiency or incidence of biochemical 
depletion is well established during intravenous nutrition. For 
example, Iron, Zinc and Copper.
2) Those where clinical deficiency or depletion although reported, 
is much rarer, for example, chromium, selenium and molybdenum.
3) Those where although the metabolic and biochemical importance 
of the element is undoubted, there are few or equivocal reports 
of deficiency or depletion during intravenous feeding. For 
example, manganese, fluoride and iodide.
This thesis deals with the experimental use of a trace element 
additive mixture given to hospital patients.
A mixture of trace elements has been available for some time 
in this country. (Addamel^ , Kabi-Vitrum, Sweden). Studies have
suggested that the amount of zinc, in particular, may be too low 
for most patients and the level of manganese may be too high.
Moreover, chromium and selenium are not present. Therefore, a
new solution (code 4854) has been formulated by Kabi-Vitrum, Sweden, 
the composition of which is being designed to meet the requirement 
of most patients receiving parenteral nutrition. This is based 
on the recommendations Shenkin & Wretlind (1974 ) ,together with levels 
of intake suggested by an expert panel of American Medical Association
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and Recommended Dietary Allowance of the United States National 
Academy of Sciences (1980).
The new essential trace element solution (code 4854) contains 
nine essential trace elements, the composition of which is shown 
in Table 2. This thesis deals with the determination of zinc, 
copper, manganese, chromium and selenium in urine and serum of 
all patient groups studied.
Methods for molybdenum, fluoride and iodide were not readily 
available, so no supplemental studies are reported.
TABLE 2
Composition of New Trace Element Solution (4854) and Addamel^
Element present 
in solution
New trace 
solution
element 
(code 4854)
Addamel^
Zinc (Zn) 1 0 0 pmol : 6.54 mg 20 pmol : 1.31 mg
Iron (Fe) 2 0 pmol : 1 . 1 2  mg 50 pmol : 2.79 mg
Copper (Cu) 2 0 pmol : 1.37 mg 5 pmol : 0.32 mg
Manganese (Mn) 15 pmol : 0.82 mg 60 pmol : 3.30 mg
Selenium (Se) 0.4 pmol : 31.58 ug —
Chromium (Cr) 0.4 pmol : 2 0 . 8  ug -
Molybdenum (Mo) 0 . 2 pmol : 19.19 ug —
Fluoride (F) 50 pmol : 0.95 mg 50 pmol : 0.95 mg
Iodide (I) 1 . 0 pmol ; 0.13 mg 1.0 pmol : 0.13 mg
Magnesium (Mg) - 1.5 pmol : 36.47 uf
Calcium (Ca) - 5.0 pmol : 0.20 mg
(The preparations comes as solution containing 3 gram Sorbitol 
and water to 1 0  ml).
17
1.3 Different Studies Undertaken
Three different studies were undertaken to evaluate the new trace 
element additive (code 4854).
1) Evaluation of new trace element solution (4854) as an additive 
to standard crystalloid infusions in post-surgical adult 
patients :
As a part of the evaluation it was necessary to assess the 
effects of infusion of essential trace metals over a short 
period of time. The possibility of abnormal serum levels 
being associated with infusion of this solution would therefore 
be detected. This was a double blind study of twenty surgical 
patients randomly divided into two groups.
Group A: Ten patients received saline and glucose (5%) for
four days post-operation.
Group B: Ten patients received 4854 additive, together with
saline and glucose (5%).
The aim of this study was to investigate the compatibility 
of trace metal additive, with saline and glucose, and to see 
the efficacy of this solution in meeting trace element require­
ments of post-operative patients receiving only crystalloid 
infusions. Furthermore, the control patients who did not 
receive the trace metal mixture supplied information as to 
the changés in serum and urine trace metals following surgical 
procedures.
2) Evaluation of trace metal solution (4854) as an additive to 
parenteral nutrition solution in post-surgical adult patients :
The aim of this study was to investigate the compatibility 
of solution 4854; and to investigate the efficacy in meeting 
the trace element requirements of patients being intravenously 
fed. Sixteen surgical patients were studied for more than 
seven days.
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3) Evaluation of trace element solution (4854) as an additive 
to parenteral nutrition solution in medical adult patients:
The aim of this study was to evaluate the 4854 solution when
added in parenteral nutrition of more stable patients. Four
patients were selected for this study, who were on intravenous
feeding for more than fourteen days.
CHAPTER 2
METHODS OF TRACE METAL ANALYSIS
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CHAPTER 2
2.1 METHODS FOR TRACE METAL ANALYSIS
Zinc
Serum zinc and urine were analysed by flame atomic absorption 
spectrophotometry (FAAS) (Peaston 1973).
0.5 ml of serum was diluted with 2.5 ml of 1C%. isopropanol and
measured against 10% isopropanol diluted 3.9, 7.8, 15.3 and 31.2
pmol/ 1  standards.
1 ml of urine was diluted with 5 ml of 10% isopropanol and 
measured against 10% isopropanol diluted 3,9, 7.8, 15.3 and 31.2
pmol/1 standards. All zinc analysis was done by routine Glasgow 
Royal Infirmary staff.
Copper
Serum copper was analysed by flame atomic absorption spectro­
photometry (Peaston 1973). 0.5 ml of serum was diluted with 2.5
ml of isopropanol and measured against 0.25, 0.5, 1.0 and 2.0 mg/1 
aqueous standards.
Urine copper was analysed by carbon furnace atomic absorption 
spectrophotometry (Halls et àl 1981). All samples were acidified 
before the analysis. 2 0 0  pi of urine diluted with the same amount 
of distilled deionised water was measured against aqueous 20, 40, 
60, 80 and 100 pg/1 Cu standards.
Manganese
Serum and urine manganese were analysed by carbon furnace atomic 
absorption spectrophotometry (Halls 1980). (Perkin Elmer model 
number 2280).
Standards : Standards were made 0, 2, 4 and 6  pg/1 of manganese
in 0.1 molar nitric acid (Aristar),
Samples : 200 pi of sample + 200 pi of distilled deionised water
in acid-washed auto sample cups.
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Instrument
Conditions
Wavelength : 279.5 nm
Slit : 0.7 nm
Normal graphite tube was used.
Background correction : ON
Scale expansion : 10 times
Injection volume : 20 pi
Stage Temp Ramp rate Hold ■
Dry 120 ^ 7 13
Ash 1100° 7 23
Atomise 2700° 2 1 0
(Gas flow 10 ml/min, Aa
Clear 2700° 2 5
Urine Manganese
Standards : Standards were made 0, 2, 4 and 6  pg/1 of manganese
in 0.1 molar nitric acid (Aristar).
Samples : 200 pi of sample + 200 pi of distilled deionised water
in acid-washed auto-sampler cups.
Instrument
Conditions : Wavelength : 279.5 nm 
Slit : 0.7 nm
Background correction : ON 
Scale expansion : 8  times 
Injection volume : 20 pi 
Normal graphite tube
Stage Temp Ramp rate Hold time (seconds)
Dry lOOO 7 13
Ash llOQO 7 23
Atomise 2700° 2  1 0
(Gas flow 30 ml/min, Az-2, Rec -2 sec) 
Clear 2700° 2 5
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Chromium 
Urine chromium
Urine chromium was analysed by carbon furnace atomic absorption 
spectrophotometry (Perkin Elmer model number 2280). The method 
was developed by Dr Halls and was as follows :
Standards : Standards were made 0, 2, 4 and 6  pg/1 of chromium
in 0.1 molar nitric acid (Aristar).
Samples : All urine samples were acidified (1 ml conc. H SO
(Aristar) to 25 ml urine) on collection. 200 pi of 
sample + 2 0 0  pi of distilled deionised water in acid
washed auto-sampler cups.
Instrument
Conditions Wavelength : 357.9 nm 
Slit : 0.7 nm 
Injection volume : 20 pi 
Background correction : ON 
Scale expansion : 20 times 
Normal graphite tube
Stage Temp Ramp rate Hold time (seconds)
Dry 1 1 0 ° 7 2 0
Ash 1 2 0 0 ° 7 2 0
Atomise 2400°
*
0
(Gas flow
5
30 ml/min, Az -2,
Clear 2700° 1 5
(* Temperature sensor attached to furnace was set at 0 ramp rate)
Serum Chromium
Standards ; Standards of 0, 2, 4 and 6  pg/1 of chromium in 0.1
molar nitric acid (Aristar) were prepared. Each stand­
ard was diluted 1:1 with serum sample low in Cr conc.
Samples : 200 pi of sample + 200 ul of distilled deionised water
in auto-sampler cups. Water blank was run.
Instrument 
Conditions :
22
Wavelength : 357.9 nm 
Slit : 0.7 nm 
Injection volume : 20 pi 
Background correction : OFF 
Scale expansion ; 20 times
Stage Temp Ramp rate Hold time (seconds)
Dry 110° 7 20
Ash 1200° 7 20
Atomise 2200° 0 5
(Interior flow 10 ml/min, Az -2, Rec 0)
Clear 2700° 1 5
All glassware was acid-washed in Aristazr 20% nitric acid, as were 
all micropipette tips and auto-sampler cups. They were then rinsed 
in deionised water and air dried.
Selenium
Analysis of selenium in urine and serum was done by hydride 
generation atomic absorption spectrophotometry. Perkin Elmer model 
number 370 was used along with MHS 10.
Principle
All samples were digested with a mixture of perchloric and 
nitric acids to remove organic material, Hydrochloric acid was 
added to the digest which was then diluted to about 25 ml. Selenium 
was then determined by hydride-generation atomic absorption spectro­
photometry, The selenium was reduced by sodium borohydride to 
give hydrogen selenide, which was carried by a stream of nitrogen 
to a heated silica-absorption cell in the light path of the spectro­
photometer. Thermal breakdown of the hydrogen selenide gave selen­
ium atoms which gave rise to an atomic absorption signal.
Reagents
Perchloric acid (72% W/V) (Aristar); Nitric acid (Aristar),
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Hydrochloric Acid (Analar), Selenium standard solution
1 mg/ml (BDH), Sodium borohydride (BDH), Sodium hydroxide 
(Analar), Hydrochloric acid was diluted 2:5 with distilled 
water to form 4 molar HCl, 3% sodium borohydride in 1% 
sodium hydroxide was prepared in distilled deionised water, 
which was used as the stock solution.
Precautions against contamination
Digestion tubes, glass beads, pipette tips, sample cups, 
were acid-washed with 2 0 % nitric acid before use.
Digestion Procedure
2 ml of urine or 0.5 ml of serum was added to digestion 
tubes. 5 ml of conc. nitric acid, 2 ml of perchloric
acid and 2 glass beads were added. Then the tubes were
placed in digestion block and heated at 1 1 0 °C for one hour, 
150° C for one hour, and 200° 0 for one hour. Tubes were 
cooled, 7 ml of 4 molar hydrochloric acid was added. The 
solution was mixed vigorously. They were heated again 
at 80° C for thirty minutes. Tubes were cooled and the 
solution was transferred into plastic containers by washing
the digestion tubes three times with distilled deionised 
water, to give a final volume of 25 ml.
Calibration Solutions
0, 20, 40 and 60 ng of selenium were added in plastic 25
ml containers. To it, perchloric acid and 2 ml of hydrochloric 
acid were added and finally diluted to 25 ml with distilled 
deionised water.
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Instrumental Conditions
Selenium EDL lamp with power supply ( 6 watts maintained 
during the analysis).
Wavelength : 196 nm
Slit : 2 nm (alternative)
Time constant : TC^
Polypropylene bottle on MHS 10 filled with sodium borohydride 
(3%) up to mark.
2.2 Sample Collection and Storage
Sample collection was the most important factors in getting 
good analytical results, since contamination could give 
misleading results. Contamination could occur by two different 
ways :
A) Collection, B) Storage. However, the contamination
problem was reduced by using the appropriate techniques
in collecting and storing the samples. The disposable 
papier-mache urine bottles were the main source of contamination 
while collecting urine (Fell et al 1980). The easily contam­
inated elements were zinc and manganese. Figures of contamin­
ation are shown in Table 3.
TABLE 3
The effect of leaving urine in papier-mache containers
on the concentration of minerals in urine
Zn Cu Mn
---(pmol/1 )—
Urine before it was put in
container 37 0.27 0 . 0 1
After 5 minutes in container 45 0 . 2 2 1 1 . 6
After 10 minutes in container 52 0 . 2 1 17.0
After 15 minutes in container 53 0.26 17.9
After 30 minutes in container 56 0.28 2 0 . 1
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Manganese increased rapidly after only five minutes 
in the paper-mache urine bottles. This unphysiological
increase of manganese concentration was used as an index 
of such contamination. To avoid this, plastic urinals
were used. For twenty-four hour collections, urine was
stored in acid-washed plastic bottles. Smaller portions
of urine were kept in a number of plastic containers, which 
were stored at 4-10°C while awaiting analysis.
It is known that when blood is taken through stainless 
steel needles it becomes contaminated (Behne 1980), partie 
ularly for manganese. This was also shown by Fell et
al (1980). Levels of contamination are shown in Table
4. To reduce this problem, a "Venflon" plastic cannula 
was used to take the blood sample. First, 10 ml of blood 
was discarded and used for routine analytical work. The 
last 2 0  ml of blood was taken into acid-washed plastic 
centrifuge tubes. After centrifuging, the serum was stored 
in plastic washed 5 ml tubes (Z5) and stored at 4-10° C 
while awaiting analysis.
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TABLE 4 .
Sequential blood samples via "Venflon" cannula
Blood samples taken Mn conc in serum pg/litre
(Mean of results from three different 
subjects)
First 10 ml of blood 0.55
Second 10 ml of blood 0.35
Third 10 ml of blood 0.35
Fourth 10 ml of blood 0.35
2.3 Clinical Experiments
The trace metal mixture (code 4854) is an aqueous preparation suit­
able for intravenous injection, the composition of which is shown 
in Table 2. One ampoule (10 ml) per day was added to the intra­
venous nutrition regimen of patients. Three studies were undertaken.
A) As an additive to standard crystalloid infusions
Twenty patients undergoing elective abdominal surgery were selected. 
Informed consent was obtained and they were divided randomly into 
two groups. One group of ten patients received only saline and
glucose (5%) intravenously for four days after operation. The
other group received in addition, one ampoule of 4854 solution
per day. Blood and twenty-four hour urine samples were collected 
prior to surgery, and blood after operation, on days 1, 3, 5 and
6 , and urine (24 hour) daily for four days after operation. All
samples were collected by procedures described previously (Section
2 .2 ) to minimise contamination, and analysed for zinc, copper, 
manganese, chromium and selenium, by atomic absorption spectro­
photometry methods (Section 2.1). The study was "double blind" and 
the code broken to identify the additive (4854) group only after
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all analyses were complete.
B ) As an additive in patients receiving; total parenteral 
nutrition after surgery (Surgical I.V.N)
Sixteen patients undergoing elective surgery were selected, 
informed consent was obtained. All the patients received 
a three litre bag of aqueous nutrients containing amino-acids 
(Vamin 9.5%), Glucose (50%), Saline (0.9%), Magnesium ( 6  
mmol). Phosphate (15 mmol), plus one ampoule of (4854) trace 
metal solution. Also, 0.5 litres fat emulsion (Intralipid
20%) and fat water-soluble vitamins (Solvito, Vitlipid), 
were supplied. This regimen supplies 3000 KCals/day and 14 grams 
of nitrogen per day. Patients were classified as either:
1) Stable anabolic patients (urine N less than 12 g/day) 
or :
2) Catabolic patients (urine N greater than 14 g/day).
Each patient was studied for at least one week. Most 
of them for two weeks or more. The regimen was infused through 
a central venous catheter.
1) Pre-infusion measurements were made for serum samples 
and for twenty-four hour urine samples.
2) Twice a week twenty-four hour urine samples and serum 
samples were analysed.
3) Final samples were obtained on the day of the last infusion.
In some patients, samples were collected twice a week 
after stopping the infusion.
C) As an additive to parenteral nutrition in medical natients 
(Medical I.V.N)
This study was to investigate more stable patients likely 
to require feeding for longer periods. Four patients were 
selected, and informed consent was obtained. Patients were
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studied for more than fourteen days. The infusion regimen
was similar to that used in the surgical I.V.N. groups.
1) Pre-infusion measurements were made on serum and twenty- 
four hour urine samples.
2) Twice a week, twenty-four hour urine samples, and serum 
samples, were analysed for a total of fourteen days, or 
more in some cases.
3) Final samples were obtained on the day of the last infusion.
In some patients, samples were obtained twice a week
after cessation of the infusion of the 4854 mixture.
2.4 Statistical Techniques
Statistical significance was evaluated by the "Mann-Whitney" 
test, because results could not be shown to have a Gaussian 
distribution in all groups, and some were clearly skewed.
The most obvious method of comparing two groups, the "T- 
test", was discarded in favour of the non-parametric equivalent, 
the Mann-Whitney test. This compares the medians of the 
two test groups, rather than their means and thus eliminates 
the bias in group means caused by either very high or very 
low outliers. This test was applied to three different studies 
as follows:
1) Crystalloid study
Each post-operative day was compared with the day prior
to the operation for both groups (with additive and without 
additive). Also, both groups were compared on each partic­
ular day throughout the study for urine and serum concen­
trations .
2) Surgical I.V.N
Both groups (anabolic and catabolic) were compared on 
each day. Also, for each group, each post-infusion day
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was compared with the pre-infusion day to see the significance 
for urine and serum trace element concentration.
3) Medical I.V.N
Each post-infusion day was compared with the pre-infusion 
day to see the significance, for urine and serum, of trace 
element concentration.
CHAPTER 3
REFERENCE VALUES
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CHAPTER 3
3.1 REFERENCE VALUES
Introduction
Each study of trace metals in biological material such as 
blood serum and urine, when present at low concentrations 
( < pmol/litre) requires confirmation that the methods of
sample collection, storage and analysis are valid and in 
reasonable agreement with the lowest published values for
healthy subjects (Versieck et al 1980). Therefore, in addition
to using the established reference ranges of Glasgow Royal 
Infirmary Biochemistry Department, it was decided to measure 
the levels of zinc, copper, manganese, chromium and selenium 
in serum and urine for fifty healthy laboratory staff.
Out of fifty volunteers, twenty-six were males and twenty- 
four females. Twenty-four hour urine was collected for two 
consecutive days, and one blood sample was taken at 1 0 . 0 0  
a.m. The subjects had fasted overnight. All samples were 
collected by the procedures described previously (Section
2.2) to minimise contamination. Samples were analysed by 
atomic absorption spectrophotometric methods (Section 2.1).
Tables 5 and 6  show the normal ranges for each element.
TABLE 5
Normal Range in Urine for Five Trace Metals
Observ
95% limit (B)
Element Mean x S.D. x - 2 S.D. (A) ed range
Zinc (pmol/vol) 9.70 4.68 0.3-19.0 3.,3 - 21.4
Copper " " 0.33 4.95 0-2.23 0 .2 0 - 0.58
Manganese
(nmol/vol) 26.5 14.1 0—54.6 5,
, 0  — 60.0
Chromium " " 2 0 . 0 1 0 . 0 0-40 6 .0 - 43.0
Selenium " " 388.0 162.0 63-1036 176,. 0 - 804.0
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TABLE 6
Normal Range in Serum for Four Trace Metals 
Element Lr. g.S-D^U.)
Zinc (pmol/vol) 14.5 1.8 10.9-18.1 12.5-17.5
Copper ’* " 15.8 2.9 10.0-21.7 11.5-23.5
“^"®^{nmol/voD 14.4 5.2 4.0-25.0 7.0-27.0
Selenium " '* 1130.9 312.0 507.0-1755.0 583.0-1646.0
From these results, two "normal ranges" can be calculated:
A) By statistical calculations
That is, the mean -  2 standard deviation, assuming Gaussian 
distribution.
B) Observed range
This was calculated by examining the frequency distribution 
for each element and then excluding the two outliers for 
urine, and one outlier for serum. This is equivalent to 
the 95% observed range. It is felt that these values are
more representative of the result actually found in the 
population studied and that the statistically derived results 
are less useful, although the convention of x - 2 S.D. is
commonly employed.
The reference values may differ according to the age 
and sex of the population. To obtain a close match with
the patient group was virtually impossible. Therefore, the
"normal range" was used as an initial guideline to evaluate 
results from the study.
A comparison of "normal values" with some published 
results are shown in Tables 7 and 8  for serum and urine, 
which clearly indicates that the "normal range" found is 
similar to other published results.
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3.3. Results 
Urine Zinc
The distribution of results appears skewed (Figure 1) with 
a normal range of 3.3-21.4 pmol/volume. A problem in measuring 
zinc is contamination during collection. Female volunteers 
were asked to avoid possible contamination of the urine by 
faecal material or menstrual blood. Results are similar to 
other published estimates (Table 8 ).
Serum Zinc
Serum zinc has a Gaussian distribution (Figure 2). The normal
range 12.5-17.5 pmol/1 which is in agreement with published
results. Since most literature results are in reasonable
agreement (Table 7), this suggests that there are no major
methodological problems in the determination of serum zinc,
assuming control over sampling technique.
Urine Copper
The distribution of results appears Gaussian (Figure 3) and 
the normal range is 0.20-0.58 pmol/volume. Values are similar 
to other published data (Table 8 ).
Serum Copper
Results show a skewed distribution (Figure 4). The normal 
range is 11.5-23.5 pmol/litre. This agrees with the published 
results (Table 7). In this study, twenty-four female subjects 
who were not taking contraceptive pills, were chosen, since 
this drug increases serum copper concentrations. large numbers
of studies have been published on serum copper concentrations 
and most are remarkably consistent even when obtained by 
different techniques ; this shows that there are no serious 
methodological problems in serum copper determination.
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Figure 1
Urine zinc excretion in fifty persons, 26 male and 
24 female.
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Figure 2
Serum zinc concentrations in fifty persons, 26 male 
and 24 female.
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Figure 3
Urine copper excretion in fifty persons, 26 male and 
24 female.
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Figure 4
Serum copper concentrations in fifty persons, 26 male 
and 24 female.
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Urine Manganese
The distribution of results appears Gaussian (Figure 5) and 
the normal range is 5.0-60,0 nmol/volume. This metal is 
difficult because of the risk of contamination and problems 
of accurate analysis at the low concentrations found in urine.
These problems are illustrated by disagreement between the 
published results (Table 8 ).
Serum Manganese
Serum manganese has a skewed distribution (Figure 6 ). The 
normal range is 7-27 nmol/volume, which is in agreement with 
a number of recently published results (Table 7). The main 
problem in determining serum manganese is in making measurements 
close to the detection limit of current CFAAS techniques 
without interference from the matrix, and in collecting and 
preparing samples without introducing contamination.
Urine Chromium
The distribution of results appears Gaussian (Figure 7), 
with a normal range 6.0-43.0 nmol/volume. "Pyro-coated" furnace 
tubes were used in analysing urine chromium by CFAAS technique, 
since these tubes give more sensitivity than normal graphite 
tubes. Also, by reducing the atomisation temperature for 
chromium, an anomalous interference from the urine matrix 
was eliminated. This element is very difficult to measure, 
since it is present in small quantities. Also, the quality 
of sample and sample preparation is decisive for final results.
There are a number of discrepancies in the literature, partly 
due to contamination and partly due to the choice of analytical 
techniques (Table 8 ).
Serum Chromium
Normal values for serum chromium could not be determined,
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Figure 5
Urine manganese in fifty persons, 26 male and 24 female
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Figure 6
Serum manganese concentrations in fifty persons, 26 
male and 24 female.
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Figure 7
Chromium excretion in twenty-three persons, 13 male 
and 1 0  female.
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Selenium excretion in fifty persons, 26 male and 
24 female.
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since the estimated levels are less than 5 nmol/litre, which 
is close to the detection limit of the CFAAS method. Therefore, 
only increases above the "normal range" can be considered 
in the study.
Urine Selenium
The distribution of results appears skewed (Figure 8 ) with 
a normal range 176-804 nmol/volume. Urinary selenium excretion 
is dietary-dependent and obviously will vary with recent 
selenium intake. Furthermore, since selenium is a volatile 
metal, possible losses during the digestion period prior 
to analysis, must be avoided. Variations in published results 
are therefore to be expected (Table 8 ).
Serum Selenium
Serum selenium has a Gaussian distribution (Figure 9), with 
the normal range 583-1646 nmol/litre, which is similar to 
some of the published results (Table 7). It is difficult 
to define a "normal range" for selenium as the geographical 
differences in selenium intake exist.
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Figure 9
Serum selenium concentrations in f i f t y  persons, 26 
male and 24 female.
CHAPTER 4
INDIVIDUAL TRACE METALS : ZINC, COPPER, 
MANGANESE, CHROMIUM AND SELENIUM
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CHAPTER 4 
ZINC
4.1.1 Introduction
Zinc has long been known to be an essential element for the 
growth and development of living things. The first reports 
demonstrating zinc deprivation in vivo appeared more than 
one hundred years ago. The universal importance of this 
metal to growth in all phyla was not appreciated until much 
more recently. An important discovery considered zinc an 
essential component of erythrocyte carbonic anhydrase. 
However, more than seventy zinc metalloenzymes have been 
identified within the past decade. Many of these are concerned
with various stages of nucleic acid and protein synthesis.
Therefore, zinc is necessary for tissue growth and regeneration, 
and the consequences of severe déficiences are serious (Riordan 
1976).
Clinical interest in zinc has increased with the description 
of symptomatic deficiency, rapidly reversible with zinc therapy.
This occurs in children with a congenital defect of zinc 
absorption (acrodermatitis enteropathica) and also in children 
and adults fed intravenously with regimens deficient in zinc. 
Malabsorption of zinc has also been found in malnourished
populations and linked to a complex syndrome of hypogonodal 
dwarfism. Undue delay in the healing of surgical wounds 
and leg ulcers is also linked to zinc deficiency (Prasad
1978).
4.1.2 Body Composition
The whole body content of zinc is around two grams. In terms 
of percentage content of the body zinc, a significant amount, 
about 2 0 %, is in skin, especially in epidermal layers, 2 0 %
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in skeletal bone and 60% in muscle mass. All metabolically 
active tissue contains zinc, but certain tissues such as 
the choroid and retina of the eye, and body fluids such as 
prostatic and seminal fluid, have especially high zinc concen­
trations. Zinc is also present in small quantities in nail 
and hair.
Zinc is unevenly distributed in whole blood, 75-88% 
of the total zinc of normal human blood being contained in 
erythrocytes (red cells); 12-22% in plasma and 3% in leucocytes 
(white cells).
4.1.3 Dietary Intake : Absorption and Excretion
The recommended dietary intake for zinc is 15-25 mg/day, 
the higher intake being suggested for pregnant and lactating 
women. The best sources of zinc are good quality animal 
or plant protein. Several factors influence the absorption
and retention of zinc and thus its availability from diet.
Phytate which is present in cereal grains, markedly impairs 
the absorption of zinc (Reinhold et al 1 9 7 6 ; Prasad et al 
(1979). Recent studies. indicate that higher, fibre , intake,; .which 
is common in subjects consuming high cereal diets, is detrimental 
to zinc availability. The binding of zinc to fibre of wheat 
is particularly important, because in contrast to other com­
ponents , fibre is not degraded by digestive secretions.
As a result, zinc remains attached to fibre and is transported 
to the large intestine where absorption does not occur. 
Ultimately, it is lost in faeces. The effect of chelating 
agents on zinc absorption has been studied in experimental 
animals. Chelating, agents form complexes with zinc from 
dietary sources and make it available for absorption, for 
example, E.D.T.A. and penicillamine act in this way.
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Normally, only a small percentage (about 8-20%) of ingested 
dietary zinc is absorbed. Absorption of zinc is difficult 
to ascertain, since excretion of zinc is nearly all via gut.
Becker et al (1971), concluded that zinc absorption is var­
iable with body size, levels of zinc in diet and presence 
in the diet of potentially interfering substances such as 
calcium, phytate, other chelating agents and vitamin D.
Once zinc is absorbed, it binds to plasma albumin in 
the portal blood and is concentrated initially in the liver. 
In peripheral blood plasma, total zinc levels are 12-18 jumol 
zinc/litre; of this, 40% is strongly bound to alpha 2-macro- 
globulin , (this zinc is not available for exchange); the 
remainder is bound to albumin (here zinc is available for 
exchange) and some is in equilibrium with a smaller amount 
of zinc amino-acid complexes (1 % of the total).
The main route of excretion of zinc is in faeces. The 
faecal output consists of both unabsorbed dietary zinc and 
endogenous zinc re-excreted into the gut. Using an oral 
dose of Zn^^ , Spencer et al (1965) showed that after twenty- 
one days, 70% of the dose is excreted in faeces, 2% in urine, 
with 28% tissue retention. Urinary zinc excretion is about 
10 jumol (650 jug/day) and is independent of dietary intake. 
Significant loss of zinc in sweat also occurs. Prasad et 
al (1963) reported 1.5 mg/1 zinc for whole sweat and 0.9 
mg/ 1  for cell-free sweat.
4.1.4 Biochemical Importance
Various studies have shown that zinc is a constituent of 
more than seventy metalloenzymes. Many of these are concerned 
in various stages of nucleic acid and protein synthesis.
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In some cases these enzymes have a catalytical function, 
while some cases metal has a role for conformation or stabil­
isation. The first demonstration of a specific biological 
function which was critically dependent on the presence of 
zinc was carbonic-anhydrase. Many enzymes involved in nucleic 
acid metabolism such as thymidine kinase, DMA polymerase, 
RNA polymerase and reverse transcriptase, require zinc for 
their activities. Most stages of both nucleic acid and protein 
synthesis are zinc-dependent, therefore cellular growth and 
tissue regeneration are affected by zinc deficiency. Recent 
studies (Prasad et al 1974), indicate that thymidine kinase 
is very sensitive to lack of zinc.
In the past few years, zinc has been found in both DNA 
and RNA polymerase. When the tissue of zinc-deficient animals 
was examined, it was found to be lower in zinc, RNA, DNA 
and total protein whereas ribonuclease activity and the concen­
tration of free amino-acids was increased (Underwood 1977). 
The activity of R.N.Ase is also regulated by exogenous zinc 
and thus, zinc appears to play a very important role in RNA 
and DNA metabolism.
4.1.5 Clinical Effects of Deficiency
For many years, it was considered virtually impossible for 
human beings to become zinc deficient. The naturally occurring 
déficiences were not due to a simple inadequacy of zinc intake, 
but rather were the result of several conditions that decreased 
the availability of dietary zinc and accelerated its loss 
from the body. Malabsorption, cirrhosis of the liver, chronic 
renal disease and other chronically debilitating diseases 
may induce zinc deficiency. In 1961, a group of eleven Iranian 
adult males were reported to show clinical features, such
43
as anaemia, hepatosplenomegaly, short stature and marked 
hypogonadism. They all gave the history of geophagia, and 
there was no evidence of blood loss or hookworm infestation.
Oral zinc therapy reversed many of these effects.
Symptoms of acute zinc deficiency include severe but 
localised skin rash with loss of head and body hair. There 
may be abdominal pain with diarrhoea, and also altered mood. 
These signs and symptoms improve rapidly, that is within 
two weeks, of adequate zinc provision. In chronic zinc deficiency 
effects noted are failure of normal growth in children and 
young adults, poor appetite and depression of the senses 
of tase and smell (Prasad 1979). A functional depression 
of immune competence has been noted in malnourished children, 
which could be reversed by zinc therapy (Golden et al 1978). 
Reduction in the rate of normal wound healing is also often 
associated with zinc deficiency (Prasad 1978),
4.1.6 Biochemical Assessment of Zinc Status
Ideally, techniques such as metabolic balance studies, should 
be performed. This will involve the measurement of total 
input from all sources, that is, dietary and intravenous, 
and total excretion by all routes, that is, urine, faeces 
and even sweat. Such studies are difficult in a clinical
situation; although demonstration of negative zinc balance 
over a period of several days or weeks is strong evidence
of impending zinc deficiency. This procedure is not practicable,- 
on a wide scale.
In addition, the dynamic aspects of zinc turnover and
distribution should be studied using radioactive or stable 
isotopes. Again, it is not practicable in clinical patients
on a wide scale. Therefore, direct analysis of zinc concen-
44
trations in serum, red cells, leucocytes, urine and hair, 
has to be used. Analysis of zinc in hair has ben suggested
as a guide to body status, but this is subject to difficulties
of interpretation. Serum zinc analysis is by far the most 
widely used inex. "Normal values" are 12.5-17.5 ^mol/1 (Table
6 ) but a large variety of non-specific factors lower serum 
zinc without the presence of tissue zinc deficiency. any
form of stress, injury or surgery, infection disease or steroid 
drugs, will lower serum zinc (Fell et al 1978). Only when 
values are persistently less than 10 ^mol Zn/1, can deficiency 
be postulated and even then serum albumin should also be 
considered.
Urinary zinc excretion, which increases as a part of 
the metabolic response to injury and infection, can also 
be a useful guide. High urine zinc excretion (greater than 
50 jamol/24 h) indicates a continuing catabolic state (or 
influence of chelating substances in intravenous fluids). 
As the patient gains weight, serum and urinary zinc will 
tend to fall, signalling the need for increased supply, to 
allow tissue regeneration.
Various factors, such as the time of sampling, techniques 
of sampling (haemolysis increases zinc levels) and of analysis, 
must be considered carefully. Indirect means of zinc assessment, 
based upon the biochemical functions of zinc, have been proposed. 
Low levels of the zinc enzyme, alkaline phosphatase, during 
deficiency, increase to within the normal range with successful 
zinc therapy. This is less useful when there is pre-existing 
liver disease, since alkaline phosphatase is already high 
in the serum of this type of patient.
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4.1.7 Zinc' in Intravenous Nutrition
The low levels of zinc present in most intravenous solutions, 
coupled with the tendency towards increased urinary losses, 
suggest that the patients requiring intravenous nutrition 
may develop zinc deficiency. In addition, serum levels of 
zinc in patients beginning intravenous nutrition are often 
less than normal. A number of recent reports have illustrated 
the relationship between serum zinc levels and treatment 
with intravenous nutrition (Kay et al 1976; Arakawa et al 
1976), which suggests that additional zinc should be provided 
to patients receiving intravenous nutrition. It is clear 
that the amount required to maintain zinc equilibrium varies 
in individual patients, dependent upon several factors.
A) Body content of zinc at the time of beginning of total 
parenteral nutrition.
B) Rate of loss of zinc in urine and faeces or by other routes.
An average intravenous supply of 100 jumol/day of zinc was 
used during the study.
4.1.8 Results of this Study 
Urine Zinc
A) Crystalloid Study
Urine excretion in both groups was similar at the start and 
on the post-operative days 1, 2, 3 and 4 (Tables 9 and 10).
There was no significant difference between the groups on 
these days. Also when each post-operative day was compared 
with the pre-operative day, there was no significant difference 
(Figure 11). At the end of the study, in the group given 
additive out of eight patients, six were within the normal 
range (3.3-21.4 yamol/volume) and two were above, while in 
the group without the additive, out of nine patients eight
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TABLE 9
Zinc in Urine, Patients with 4854 Infusion
No. Name Pre-op Days Post-op (pmo 1 /vol)
1 2 3 4
1 J.B 11.9 6.7 7.5 1 1 . 8  , 15.1
2 J.M 9.7 7.7 7.2 12.5 1 0 . 2
3 S.M 9.3 6.9. 1 0 . 8 14.1 25.5
4 W.W. 3.2 9.0 5.5 8.7 9.5
5 C.M * * * * *
6 W.A 17.7 12,3 14.5 23.1 28.2
7 J.S * 6.9 6 . 2 8.3 9.2
8 B.S 3.3 10.7 1 0 . 2 10.5 1 0 . 0
9 W.R 7.5 16.2 * * *
1 0 A.P 4.6 1 . 6 5.9 5.7 6 . 8
Mean 8.4 8.7 8.5 1 1 . 8 14.3
S.D 4.9 4.1 3,1 5.3 8 . 1
TABLE 10
Zinc in Urine, Patients without 4854 Infusion
No. Name Pre-op Post--op (pmol/vol)
1 2 3 4
1 M.M 6.3 9.6 7.1 1 0 . 6 13.5
2 A.C 3.9 3.5 3.3 4.6 8.5
3 W.L 10.5 14.9 13.7 15.3 16.5
4 J.M 4.3 6 . 1 12.9 15.0 14.3
5 M.M 8 . 1 8 . 0 17.7 9.7 13.8
6 H.S 12.4 8 . 8 6 . 8 15.5 16.5
7 J.M 34.5 8 . 8 16.9 13.3 9.0
8 T.C 33.7 * * * *
9 R.M 14.8 28.7 2 1 . 8 * 25.6
1 0 H.S 6.4 9.2 13.1 6.9 9.5
Mean 13.5 10.5 1 2 . 6 11.4 14.1
S.D 11.4 7.5 5.9 4.1 5.3
* Urine contaminated
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were within the normal range and one was above.
B) Surgical I.V.N
Both anabolic and catabolic surgical patients started with 
a high zinc excretion (35.0 ~  22.2 ^mol/volume for anabolic 
patients; 68.3 i 7.6 ^mol/volume for catabolic patients) (Table 
11 and 12). There was no significant difference between
the groups on starting day, but there was a significant diff­
erence (P less than 0.05) throughout the study (Figure 12). 
At the end of the study zinc excretion was 54.6 i 22.0
jumol/volume for anabolic patients and 115.7 i 32.7 pmol/volume
for catabolic patients. All eight patients from the anabolic ■ 
group and all three patients from the catabolic group, were above 
the normal range for urine zinc excretion.
C) Medical I.V.N
In this group, zinc excretion starts above the normal range 
(Table 13) and remains the same throughout the study (Figure
13). On days 1-4, zinc excretion of all four patients was 
above the normal range; on days 9-12, three patients were 
above and one was within the range. At the end of the study, 
one patient was above, and one was within the normal range.
Serum Zinc
A) Crystalloid Study
Both groups, prior to operation, started within the normal 
range (with additive 13.5 i 2.7 yumol/1 and without additive
12.9 i 2.9 yumol/1). On post-operative day 1, serum zinc
dropped considerable in both groups, and was below the normal 
range (Tables 14 and 15). When this day was compared with 
the day prior to the operation, there was a significant differ­
ence (P less than 0.05). Serum zinc started to increase 
from day 4 (Figure 14). At the end of the study the mean 
zinc concentration in the group without additive was 1 2 . 0
Zinc in Urine,
TABLE 11 
, Surgical I.V.N. Study
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ANABOLIC GROUP
No. Name Pre-Infusion
(yumol/vol)
Post-Infusion Days 
Mean 1-3 8-10 15-17
Stopping
Value
1 W.M — 30.3 38.1 18.8
2 J.W - 40.3 53.5 61.8 ■ -
3 J.T - 28.0 50.3 - ■ -
4 I.P 34.1 19.7 21.3 37.3 —
5 D.M 64.1 55.9 78.1 56.9 -
6 J.N - 34.3 39.1 54.7 -
7 M.K - - 54.2 1 0 1 . 1 -
8 M.G 10.5 - - 47.0 —
9 W.W - 71.3 50.2 55.3 -
1 0 A . G 32.4 - - 26.1 -
Mean 35.0 39.6 47.9 54.6 18.8
S.D 2 2 . 2 17.8 16.4 2 2 . 0 -
TABLE 12
CATABOLIC GROUP
No. Name Pre-Infusion Post-■Infusion Days Stopping
(jumol/vol ) Mean 1-■3 8-10 15-17 Value
1 A.G 75.1 6 6 . 6 61.4 — —
2 A.M 73.2 72.6 61.0 - -
3 D.M 58.1 - 66.4 - -
4 H.W - 91.8 41.9 78.2 -
5 I.C 67.4 109.0 115.4 132.0 61.1
6 G.R — 112.7 105.0 137.4 -
Mean 68.3 90.0 74.8 115.7 61.1
S.D 7.6 20.9 28.7 32.7 —
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TABLE 13
Zinc in Urine, Medical I.V.N. Study
No, Name Pre-Infusion Post-Infusion Days
(^mol/vol ) Mean 1-4 9-12 17-20 25-28
1 R.M - 38.6 49.2 - -
2 P.P - 24.8 18.4 16.6 19.2 ^
3 E.I 58.8 50.8 45.8 59.9 48.1
4 J.C 24.2 21.7 28.6 49.6 -
Mean 41.5 34.0 35.5 42.0 33.7
S.D 17.3 1 1 . 6 1 2 . 6 18.5 14.5
50
TABLE 14
Zinc in Serum, Patients with 4854 Infusion
No. Name Pre-op
Days
Post-op (yumol/1 )
1 3 5 6
1 J.B 14.5 11.5 1 2 . 0 16,0 • 14.0
2 J.M 13.5 8 . 0 11.5 1 1 . 0 1 1 . 0
3 S.M 14.0 5.0 1 0 . 0 15.0 15.5
4 W.W 11.5 8.5 1 0 . 0 12.5 11.5
5 C.M 20.3 13.5 18.3 25.0 2 1 . 0
6 W.A 14.3 9.5 1 0 . 0 13.0 17.3
7 J.S 13.5 8.5 8.5 1 1 . 0 11.5
8 P.S 1 0 . 0 9.0 1 0 . 0 14.5 13.0
9 W.R 12.5 1 1 . 0 1 1 . 0 15.0 13.0
1 0 A.P 1 2 . 0 8.5 1 1 . 0 14.5 12.5
Mean 13.6 9.3 1 1 . 2 14.8 14,0
S.D 2.7 2.3 2.7 3.9 3.1
TABLE 15
Zinc in Serum, Patients without 4854 Infusion
No. Name Pre-op Days Post- (^mo
5
1 /1 )
1 3 6
1 M.M 1 0 . 0 9.5 1 0 . 0 10.5 10.7
2 A.C 11.5 7.5 8 . 0 10.5 12.5
3 W.L 1 2 . 0 9.5 1 1 . 0 12.5 11.5
4 J.M 13.0 8.5 1 0 . 0 13.5 14.0
5 M.M 1 2 . 0 7.5 10.5 1 2 . 0 12.5
6 H.S 15.0 7.0 9.5 13.5 13.5
7 J.M 8.5 8.5 8 . 0 8 . 0 9.5
8 T.C 14.5 12.5 1 2 . 0 14.0 13.5
9 R.M 13,0 9.0 14.0 12.5 13.5
1 0 H.S 19.5 14.0 1 0 . 0 15.0 13.0
Mean 12.9 9.4 10.3 11.3 11.9
S.D 2.9 2 . 2 1 . 8 4.1 1.9
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- 1 . 6  yumol/1 , which is below the normal range, while the
group given additive was 14.0 - 3.1yumol/1, within the range.
In the group given the additive, at the beginning of 
the study, out of ten patients six were within the normal 
range, three were sub-normal and one was above. On post­
operative day 1 , eight patients were sub-normal and two were 
normal. On post-operative day 3, nine patients were sub­
normal and one was normal. On day 5, seven patients were
normal, two were sub-normal and one was above. On the last 
day, six patients were normal, three sub-normal and one above. 
In the group without the additive, at the beginning of the 
study, out of ten patients five were sub-normal, four normal, 
and one was above. On post-operative day 1, eight patients 
were sub-normal and two were normal. On day 3, nine patients 
were sub-normal and one was normal. On post-operative day 
5, six patients were normal four were sub-normal. On the 
last day, seven patients were normal and three were sub-normal.
Serum albumin also dropped considerably on post-operative 
day 3 (Figure 17). There was no significant difference between 
the groups throughout the study (Tables 19 and 20).
B) Surgical I.V.N
The anabolic group started with a normal zinc concentration (Table 
16), while the catabolic group was below the normal range 
(Table 17). In the anabolic patients, zinc remained the 
same throu^ iout the study, and at the end of the study the mean 
zinc concentration was 14.8 - 4.0 ^ mol/1, while in the catabolic
group, it started to increase from days 7-11 and at the end
of the study it was 17.0 - 5.6 jumol/1. There was no significant 
difference between the groups throughout the study. At the
end of the study, in the anabolic group, out of five patients
TABLE 16
Zinc in Serum, Surgical I.V.N. Study 
ANABOLIC GROUP
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No, Name Pre-Infusion Post-Infusion Days
Stopping
Value(^mol/1 ) Mean 1--4 7-11 14-18
1 W.M — 9.0 1 1 . 8 — 13.7
2 J.W 21.5 21.3 18.1 16.9 19.7
3 J.T 1 1 . 0 — 10.5 - -
4 I.P 1 2 . 0 9.3 — 15.5 -
5 D.M 16.5 1 0 . 0 1 2 . 0 - 13.5
6 J.N 8.5 12.5 13.5 13.8 -
7 M.K 13.0 - 2 0 . 0 17.8 -
8 M.G 7.5 11.5 8.5 7.0 -
9 W.W 15.5 14.7 15.5 16.9 19.7
1 0 A.G 1 2 . 0 - 1 1 . 0 14.0 10.5
Mean 1 2 . 8 12.3 13.1 14.0 14.8
S.D 4.2 4.2 3.9 3.4 4.0
TABLE 17
CATABOLIC GROUP
No." Name Pre-Infusion Post-Infusion Days
Stopping
Value
(|imol/l) Mean 1-4 7-11 14-18
1 A.G 13.0 11.5 13.5 - -
2 A.M - 1 1 . 2 9.3 10.5 -
3 D.M 7.5 1 1 . 0 11.5 -
4 H.W 14.0 1 0 . 0 1 2 . 0 22.5 13.5
5 I.C 10.5 12.5 14.5 15.0 -
6 G.R - 1 0 . 0 16.5 16.3 21.5
Mean 1 1 . 0 1 0 . 8 12.5 15.8 17.0
S.D 3.2 0 . 8 2.4 4.9 5.6
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three were within the normal range and two were above. In 
the catabolic group, both patients were above the normal 
range (Figure 15).
C) Medical I.V.N
In this group, patients started below the normal range (7.8
- 0.9 yumol/1) and rose steadily up to days 7-11, then remained 
the same until the end of the study (Table 18 and Figure 
16). At the end of the study, zinc concentration was 10.5
- 1.6 yumol/1. Of three patients, two were sub-normal and 
one was within the normal range.
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TABLE 18
Zinc in Serum, Medical I.V.N. Study
No. Name Pre-
Inf Post-Infusion Days (umol/1 ) Stopping
ValueMean 1-4 7-11 14-18 21-24 28-32
1 R.M 6 . 8 6 . 0 8.5 - - 12.5
2 P.P - 6 . 0 8.3 9.0 9.0 5.3 10.5
3 E.I 9.0 15.3 11.9 1 2 . 6 1 2 . 6 15.3 8.5
4 J.C 7.5 - 1 1 . 0 11.5 - - -
Mean 7.8 9.1 10.4 10.4 1 0 . 8 10.3 10.5
S.D 0.9 4.4 1.5 1.7 1 . 8 5.0 1 . 6
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TABLE 19
Serum Albumin, Patients with 4854 Infusion
No. Name Pre-op Days Post-op (g/l)
1 3 5 6
1 J.B 41.0 40.0 35.0 38.0 39.0
2 J.M 43.0 38.0 36.0 35.0 33.0
3 S.M 46.0 38.0 33.0 36.0 35.0
4 W.W 38.0 33.0 32.0 33.0 33.0
5 C.M 39.0 38.0 32.0 36.0 35.0
6 W.A 39.0 31.0 29.0 27.0 35.0
7 J.S 38.0 33.0 29.0 28.0 31.0
8 P.S 30.0 33.0 30.0 28.0 31.0
9 W.R 37.0 35.0 33.0 32.0 35.0
1 0 A.P 38.0 37.0 37.0 34.0 34.0
Mean 38.9 35.6 32.6 32.7 34.1
S.D 4.2 3.0 2 . 8 3.9 2.3
TABLE 20
Serum Albumin, Patients without 4854 Infusion
No, Name Pre-op
Days
Post--op (g/l)
1 3 5 6
1 M.M 31.0 30.0 29.0 28.0 30.0
2 A.C 40.0 38.0 37.0 29.0 31.0
3 W.L 36.0 35.0 32.0 31.0 32.0
4 J.M 42.0 35.0 33.0 34.0 36.0
5 M.M 37.0 35.0 30.0 31.0 31.0
6 H.S 43.0 38.0 34.0 36.0 37.0
7 J.M 36.0 32.0 30.0 29.0 30.0
8 T.C 36.0 32.0 28.0 30.0 29.0
9 R.M 34.0 33.0 30.0 33.0 32.0
1 0 H.S 43.0 39.0 31.0 34.0 34.0
Mean 37.8 34.7 31.4 31.5 32.2
S.D 4.0 3.0 2.7 2 . 6 2.7
TABLE 21
Serum Albumin, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(g/l) Mean 1--4 7-11 14-18
1 W.M - 25.0 29.0 - 32.0
2 J.W 38.0 39.0 36.0 35.0 36.0
3 J.T 30.0 - 27.0 - -
4 I.P 6 . 0 33.0 - 33.0 39.0
5 D.M 33.0 35.0 31.0 - 34.0
6 J.N 33.0 28.0 31.0 - 31.0
7 M.K 25.0 29.0 34.0 32.0 -
8 M.G 24.0 23.0 25.0 23.0 27.0
9 W.W 26.0 26.0 26.0 30.0 33.0
1 0 A.G 25.0 - 29.0 31.0 26.0
Mean 26.7 29.8 29.8 30.7 32.3
S.D 9.1 5.5 3.6 4.1 4.3
TABLE 2 2
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(g/l) Mean 1-4 7-11 14-18
1 A.G 26.0 24.0 31.0 — —
2 A.M - 24.0 25.0 25.0 -
3 D.M 2 2 . 0 26.0 27.0 - -
4 H.W 26.0 23.0 30.0 36.0 37.0
5 I.C 25.0 23.0 25.0 28.0 26.0
6 G.R - 2 2 . 0 35.0 38.0 42.0
Mean 24.8 23.7 28.8 31.8 35.0
S.D 1.9 1.4 3.9 6 . 2 8 . 2
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TABLE 23
Serum Albumin, Medical I.V.N. Study
No.' Name Pre-
T'ri'T
Post-Infusion Days (g/l)
Stopping
Value
i.ni
Mean 1-4 7-11 14-18 21-24 28-32
1 R.M 2 0 . 0 2 1 . 0 32.0 28.0
2 P.P — 23.0 25.0 31.0 32.0 27.0 26.0
3 E.I 31.0 32.0 32.0 35.0 34.0 36.0 34.0
4 J.C 2 2 . 0 - 31.0 32.0 - - -
Mean 24.3 25.3 29.3 32.5 33.0 31.5 29,3
S.D 5.9 5.9 3.8 1.7 1.4 6.4 4.2
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4,1.9 Discussion 
Zinc excretion
The main route of zinc excretion is normally via the gastro­
intestinal tract, consisting of both unabsorbed dietary zinc 
and zinc re-excreted into the lumen of the gut in various
secretions. However, in the patient studies, all zinc was 
given intravenously and little or no faecal material is passed 
during total intravenous nutrition. Therefore, for practical 
reasons, no attempt was made to collect the faecal output 
and it is therefore assumed that the principal route of loss 
of zinc and other metals is in urine.
For the purpose of comparison, the total urinary output 
over the period of the study in each patient group was calculated, 
and then expressed as a percentage of the known intravenous 
dosage given during the same period. This gives an approximate 
idea of the relative retention and loss for each metal.
1) Crystalloid Study
The calculated percentage of urinary excretion was 9.9 1 4.7%
of the total infused dose of 400 yumol (26.16 mg) zinc. Thus,
about 90% of the infused zinc is retained by the patient.
Since the "crystalloid" group receive no energy or nitrogen 
input, they are mildly catabolic. They are in negative nitrogen 
balance excreting about 10.5 t 4.3 g/l of nitrogen. This 
could explain the increasing excretion of zinc at the end 
of the four day period (Figure 11), since zinc is lost in 
urine, together with other products of tissue catabolism 
(Fell et al 1977).
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2) Surgical and Medical I.V.N
In the surgical group, the anabolic patients had an average 
zinc output of 46.7 - 16.7%, retaining therefore, about 53%
of the infused dose. Whereas the more catabolic surgical
patients excreted some 84.2 i 26.8% of the infused zinc, 
retaining about 15% only of the zinc infusion. The medical 
I.V.N. group excreted 37.1 -  13.6% of their infused zinc
and retained about 63%.
The surgical anabolic group and the medical I.V.N. group 
therefore behave similarly and retain more than half of the 
zinc infusion. The more ill catabolic surgical patients 
are possibly in negative overall balance due to increased 
tissue breakdown.
A similar tendency was reported by Askari et al (1979) 
in fourteen trauma patients. Thirteen patients had skeletal 
injuries and one had gunshot wounds. The number of days 
studied per patient varied from nine to thirty days. The 
zinc excretion in these patients was three to four times 
more than normals. (9 normal subjects excreted 504 yag zinc/day 
and fourteen trauma patients 2534 pg zinc/day). These results 
are similar to the above study results. Also, Fell et al
(1977) have shown that in severely catabolic patients, some 
three to five weeks after a 55% burn injury, there is a greatly 
increased urinary zinc excretion.
All these results suggest that there is a response to
injury or trauma whereby urinary zinc excretion increases 
according to the degree of stress.
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Serum Zinc
1) Crystalloid Study
The patients from both groups prior to operation started 
within the normal range of serum zinc, but the level drops 
rapidly after the operation, as a response to the stress 
of surgery. The serum zinc concentration then increases 
steadily (Figure 14). By the end of the study (day 6 ), the
treated group had serum zinc values within the normal range.
However, the untreated group had values just below the lower 
limit of normal. This suggests that the infused zinc was 
being utilised by these patients.
Hallbook et al (1978) studied forty-five patients subjected 
to surgical trauma. The patients were randomly distributed
into two groups. One group received 20 mg zinc (307 yumol 
zinc) and 1.2 mg copper (19 jumol) per day intravenously, 
and the other did not. There was a fall in serum zinc concen­
tration in both groups after operation. The fall was more 
pronounced in the patients not receiving zinc. Serum zinc
concentrations then increased steadily. These results are
similar to the results reported in this study.
Tengrup et al (1977) studied forty-nine patients. They 
were divided into five different groups. One group of thirteen 
patients subjected to cholecystectomy was similar to this
study. He also found that after operation, there was a fall
in serum zinc concentration, and then it increased steadily.
Total serum zinc values are affected by the level of 
zinc binding proteins present in circulating blood. The
main effective transport protein appears to be albumin.
Therefore, levels of this protein should be considered when 
discussing serum zinc results. Serum albumin in both groups 
starts at the same concentration, drops considerably and
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then increases steadily, parallel to the serum zinc changes 
(Figure 17).
Hallbrook et al (1978) found serum albumin to be slightly 
higher in patients given extra zinc and copper. Serum albumin
also fell and increased later. There was a correlation between 
serum zinc and albumin. These findings are similar to the
results reported in this thesis.
After injury or stress, protein synthesis in the liver 
switches off or decreases, also albumin is redistributed 
into extravascular spaces. Therefore, a fall in serum zinc 
levels is observed, as 60% of the zinc present in serum is 
bound to albumin. Hence the provision of intravenous zinc 
during the post-operative period is unlikely to influence 
such effects, as zinc supply will not be limiting at this
stage. Although in the "crystalloid group" extra zinc provision 
does increase the serum zinc concentration, it is unlikely 
to be of clinical benefit. Zinc supply is of more use during 
long-term treatments.
2) Surgical and Medical I.V.N
The anabolic and catabolic surgical patients started within 
the normal range, and remained the same throughout the study.
Although in the catabolic patients, serum zinc concentration 
increases at the end of the study, it is not a significant 
rise. Serum albumin results are parallel to serum zinc results 
in both groups (Figure 18), In medical patients, serum zinc 
starts at the lower limit of normal and then it rises to 
normal, and remains the same throughout the study. This 
suggests that the zinc infused was being utilised by these 
patients.,
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Conclusions
Various authors have reported zinc deficiency during intravenous 
nutrition (Strobel et al 1978; Gordon et al 1978; Suita et 
al 1978; Latimer et al 1980, and Sorouji et al 1978). Oral
therapy with zinc sulphate is widely used. A dosage of 50 
mg zinc per day should correct most deficiencies. Higher 
dosage, 150 mg zinc per day, was originally prescribed but
this could be excessive and may cause malabsorption of other 
elements, such as copper.
The intravenous requirmement varies with the type of
patient under treatment, and the extent of their losses.
For the majority of the patients, 100 ^mol (6.54 mg) 
zinc per day provided, is quite enough to avoid depletion 
or deficiency, and to maintain serum zinc concentrations
within the normal range. However, for the patients with 
extensive fistula and faecal losses, more zinc may be necessary.
The American Medical Association suggested the intravenous 
supply of zinc 2.5-4.0 mg (38.2-61.2 ^mol) for stable patients 
and an additional 2 mg for adult catabolic patients. Persistent 
hypoproteinaemia is reported by Fodor et al (1972) in a severely 
zinc deficient patient, and is only improved when substantial 
zinc replacement therapy is given.
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Comparison of zinc excretion in two groups of ten 
patients, with 4854 and without 4854 infusion.
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Comparison of serum zinc concentrations in two groups 
of ten patients, with 4854 and without 4854 infusion.
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Excretion of zinc in ten anabolic patients and six 
catabolic patients receiving 4854 infusion.
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Figure 15
Serum zinc concetrations in ten anabolic patients 
and six catabolic patients receiving 4854 infusion.
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Serum zinc concentrations in four medical patients 
receiving 4854 infusion.
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Comparison of serum albumin in two groups of ten 
patients with 4854 and without 4854 infusion.
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Serum albumin in ten anabolic patients and six 
catabolic patients receiving 4854 infusion.
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Serum albumin in four medical patients receiving 
4854 infusion.
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COPPER
4.2.1 Introduction
The existence of copper in both plant and animal tissues 
was recognised in the early 19th century. The concept of
copper deficiency in man was not widely accepted. During 
the past few years, copper deficiency has been reported in 
premature infants, in malnourished infants fed exclusively 
by the intravenous route and also in adults. There are a 
number of enzymes which contain copper. These cuproenzymes 
play a vital role in many physiological functions in man 
and animals (Boyd O'Dell 1976). Copper is involved in the
development and maintenance of cardiovascular and skeletal 
integrity, central nervous system structure and functions, 
and in iron metabolism.
Anaemia, defects in connective tissue formation, albunism n, 
brain disease (Menke's kinky hair syndrome) and muscle inco­
ordination, are some of the many pathological manifestations 
caused by copper deficiency.
4.2.2. Body Composition
The whole body copper content of the adult is about 80 mg.
Neonates have higher copper concentration thaii adults ; 200
mg/kg body weight which then falls to about 30 mg/kg. The 
distribution of the total body copper among the tissue varies. 
Liver contains a significant amount of copper. In general 
terms, copper distribution can be described as;
Liver : 1.47- 3.9 ^ g/g wet weight 
5.6 1 0.2 j J L g / g wet weight 
2.1 - 0.4 jug/g wet weight 
0.7 i 0.02 jug/g wet weight
Brain
Kidney
Muscle
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In blood, copper occurs in erythrocytes ' (where it is 
believed to be mainly bound to super-oxide dismutase) and 
plasma. Plasma contains about 15-26 ^mol/1 of copper, but
is affected by age and sex.
In plasma, 90% of copper is bound to caeruloplasmin.
4.2.3 Dietary Intake, Absorption and Excretion
The recommended dietary intake for copper is 2 mg/day (31.5 
jumol/1. The average diet contains 2-5 mg/day (31.5-78.7 
pmol/day) copper. A diet which contains more vegetables
eind refined foods has less copper content. Certain foods 
such as shellfish and organ meat like liver and kidney, are 
rich in copper content.
Copper is mainly absorbed from the duodenum in man.
Copper absorption and retention is affected by the chemical 
forms in which the metal is ingested, and by the dietary 
levels of several other minerals and organic substances.
Inorganic compounds of zinc, cadmium and molybdenum in the
2—presence of SO^ excess iron and calcium, depress absorption 
of copper. Once copper is absorbed, it enters the blood 
plasma from the intestine and becomes loosely bound to serum 
albumin to form the small, direct reacting pool of plasma
copper. In this form, it is distributed widely to the tissue
and can pass readily into erythrocytes. Copper albumin serum 
pool also receives copper from tissue. The copper in caerulo­
plasmin does not appear to be readily available for exchange.
Copper then reaches the liver and is incorporated into the 
mitochondria, microsomes, nuclei and soluble cell fractions.
The copper is either stored in these sites or released for 
incorporation into caeruloplasmin and various copper-containing
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enzymes. ■ Caeruloplasmin is synthesised in liver and secreted 
into serum. The hepatic copper is also secreted into the 
bile and excreted via this route back to the intestinal contents, 
Much smaller amounts of copper also pass directly from the 
plasma into the urine or through the intestinal wall. A 
high proportion of ingested copper appears in faeces. Most 
of this normally consists of unabsorbed copper.
Intravenous injection of copper, resulting in elevated 
blood and tissue copper levels, is followed by a greater 
excretion of copper in bile, hence in faeces, but does not 
normally raise urinary output (Underwood 1977). Negligible 
amounts of copper are lost in sweat and comparatively small 
amounts in the normal menstrual flow.
Figure 10 
Dietary copper Intestine Faeces
2.0-5.0 mg 2 .0-5. 0  mg
Urine
0.01-0.06
mg
Tissue
Liver
Kidney 
0 . 6  mg
Caerulo­
plasmin
2 . 8  mg
NON-E
R.B.C.
Cu ALB
0 . 2  mg
Non-E = Non erythrocupr oprotein 
B.M. = Bone marrow 
R.B.C. = Red blood cells
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4.2.4 Biochemical Importance
There are a number of cuproproteins, in which there is a
characteristic ratio between moles of protein and atoms 
of associated copper. The contained copper does not dissociate 
during isolation of the protein and they function as enzymes.
These include caeruloplasmin, superoxide dismutase, cytochrome 
C oxidase, lysyl oxidase, tyrosinase and dopamine beta-hydroxy- 
lase. Copper metalloproteins exist in liver, red cells and
other tissues. The incorporation of iron into haem requires 
the copper enzyme ferroxidase. The beta-globulin caeruloplasmin 
is able to oxidase aromatic amines in vitro. This protein 
may also serve as a transport protein for copper. The metal, 
although tightly bound to the protein, is taken up by specific
cell receptors. From animal studies, the importance of
copper to elastin and collagen synthesis, is clear as is 
the role of various copper enzymes in the central nervous
system.
Inborn Genetic Errors
A) Menke's Syndrome
This is a fatal defect in young children, presenting as neuro­
logical damage and arterial and bone lesions^ -.fch'fer.-- ,
hair changes (steely or kinky hair). The disease may be
due to failure of intestinal and other cell membrane transport. 
This condition cannot be reversed by copper therapy.
B) Hepatolenticular Disease (Wilson's Disease)
This is also a genetic error in which copper absorption in
the gut is normal but intracellular copper metaboloism is
abnormal. The failure of copper excretion in bile, leading 
to a gradual build-up of toxic levels in liver, then in kidney 
and brain.
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4.2.5 Clinical Effects of Deficiency
A wide variety of disorders has been associated with dietary 
deficiency of copper. They include anaemia, depressed growth, 
bone disorders, depigmentation of hair and wool, heart failure, 
cardiovascular defects and gastrointestinal disturbances.
The extent to which one of these dysfunctions is actually 
revealed depends upon the species, its age and sex.
Copper deficiency mainly occurs in premature babies 
and in infants suffering from malnutrition who have been 
fed exclusively on a cow milk diet. A marked anaemia which 
is resistant to iron therapy, neutropenia (less white cells) 
and signs of intestinal malabsorption with diarrhoea are 
reported. Children who fed intravenously with copper deficient/” 
regimens have similar signs and symptoms, but in addition, 
there are bone abnormalities. Adults receiving prolonged 
intravenous feeding may also develop copper deficiency. 
This deficiency can be corrected by supplying copper either 
orally or intravenously.
4.2.6. Biochemical Assessment of Copper Status
1) Serum copper measurement and /or assay of plasma caerulo­
plasmin gives a reasonable guide to copper status. Many 
clinical conditions tend to increase serum copper non- 
specifically. If serum copper is below 10 j a m o l / 1 . ,  it suggests 
that copper deficiency may develop.
2) Abnormally high liver copper concentration is also a char­
acteristic of a number of diseases.
3) Since urine copper is normally low (less than 1 yumol/day) 
is not a useful measure of copper deficiency. Also,, 
administration of chelating agents (such as amino-acid 
infusion) increases urinary copper (Tyrola et al 1982).
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4) The direct measurement of red cell copper is possible 
and the activity of the red cell enzyme superoxide dismutase 
can be measured.
5) The copper protein, caeruloplasmin, appears to be involved 
in the conversion of iron from ferrous to ferric state.
This is required for the transformation of iron into 
haemoglobin. A clinical effect of severe copper deficiency 
is therefore an iron deficiency anaemia.
4.2,7 Copper in Intravenous Nutrition
Long-term parenteral nutrition with infusion fluids which 
have not been supplemented with copper, may lead to deficiency. 
Low birth weight infants go into negative nitrogen balance 
from birth and there may also be substantial losses of trace 
minerals in excreta (Shaw 1973). Also, intestinal absorption 
of nutrients is poor. There have been some reports of copper 
deficiency in low birth weight infants (Al-Rashid et al 1971; 
Sann et al 1978). Severe hypocupraemia, neutropenia and 
extensive bone changes have been observed in infants and 
children receiving inadequate amounts of copper when fed 
intravenously (Karpel et al 1972; Heller et al 1978). Solomons 
et al and Fleming have shown that the administration of total 
parenteral nutrition without copper, resulted consistently 
in a decrease in serum levels. A dosage of 5 mg/day (20 ^mol), 
was used by Dunlap et al (1974) to treat patients with haemato- 
logical abnormalities and biochemical signs of copper deficiency. 
The AMA recommended intravenous supply is 50-1500 jig, copper 
(8-24 ^mol). In this study, 20 ^mol (1.27 mg) copper per 
day was used intravenously.
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4.2.8 Results of this Study 
Urine Copper
A) Crystalloid Study
Urine excretion in both groups was at the same level at the 
start and on post-operative days 1, 2 and 3 (Figure 2 0 ).
There was no significant difference between the groups on 
these days. However, on day 4, there was a significant increase. 
Patients given the additive (4854) excreted 0.84 - 0.48yumol/vol) 
which is above the normal range of (0.20-0.58 yumol/vol) (Table 
24). Out of nine patients, three were within the normal
range, while six were above. In the group without the additive, 
on day 4, excretion was (0.47 - 0.19 yumol/vol) (Table 25).
Out of ten patients, seven were within the normal range 
while three were above.
B) Surgical I.V.N
Both anabolic and catabolic surgical patients started with 
a high copper excretion (0.6 - 0.9 yumol/vol) for anabolic
patients and (1 , 6  - 0 . 6  yumol/vol) for catabolic patients
(Tables 26 and 27). There was no significant difference 
between the groups throughout the intravenous feeding period 
(Figure 21). The copper excretion throughout was above the 
normal range. In the anabolic group on infusion days 15-
17, out of nine patients, one was within the normal range, 
while eight patients were above the normal range.
C) Medical I.V.N
Copper excretion prior to infusion in this group was normal, 
(Table 28), but was above the normal range through the infusion 
period (Figure 22). The copper excretion was constant during 
the study period. On days 1-4, out of four patients, two
were within the normal range and two were above ; days 9-12
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TABLE 24
Copper in Urine, Patients with 4854 Infusion
No. Name Pre-op Days
1
Post'
2
(yumol/vol) 
3 4
1 J.B 0.48 0.40 0.39 0.64 0.67
2 J.M 0.37 0.55 0 . 6 8 0.73 0.61
3 S.M 0.36 0.61 1.42 1.64 1.80
4 w.w 0.24 0.76 0.39 0.28 0.48
5 C.M * * * * *
6 W.A 0.23 0.43 0.30 0.52 0 . 6 8
7 J.S 0.29 0.40 0.40 0.46 0.48
8 P.S 0.18 0.75 0.57 1 . 0 0 1.48
9 W.R 0.49 0.65 0.58 0.48 0.51
1 0 A.P 0.33 0.50 0.52 0.84 0 . 8 8
Mean 0.33 0.56 0.58 0.73 0.84
S.D 0 . 1 1 0.14 0.34 0.40 0.48
TABLE 25
Copper in Urine, Patients without 4854 Infusion
No, Name Pre-op
Days
Post-°P (jumo1 /vol)
1 2 3 4
1 M.M 0.06 0.28 0 . 1 2 0.26 0.24
2 A.C 0.31 0.76 0.47 0.38 0.47
3 W.L 0.39 0.31 0.40 0.27 0.60
4 J.M 0.30 0 . 2 2 0.69 0.30 0 . 2 0
5 M.M 0 . 2 0 0 . 2 1 0.71 0.53 0.49
6 H.S 0.52 0.53 0.33 0.49 0.56
7 J.M 0.81 0.28 0 . 6 8 0 . 6 8 0.34
8 T.C 0.46 0.52 * 0.54 0.33
9 R.M 0.44 1 . 0 1 0.64 * 0.60
1 0 H.S 0.48 1.25 1 . 2 0 0.81 0.84
Mean 0.40 0.54 0 . 6 6 0.47 0.47
S.D 0 . 2 0 0.36 0.37 0.19 0.19
*  Urine contaminated
TABLE 26
Copper in Urine, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(yumol/vol ) Mean 1--3 8-10 15-17
1 W.M 2.19 2.54 1.54
2 J.W - 1.49 1.08 0.93 0.43
3 J.T - 0.81 0.91 — -
4 I.P 0.38 0.33 0.29 0.42 -
5 D.M 0.35 1.24 1.04 0 . 6 8 0 . 6 6
6 J.N - 1 . 1 0 1.05 1.30 -
7 M.K 2.41 2.58 1.61 1.40 -
8 M.G 0.36 0.43 1.03 0.73 -
9 W.W - 0.60 0.80 1.28 -
1 0 A . G 1.39 - - 1 . 1 2
Mean 0 . 6 0 . 8 0 . 8 0 . 6 0.54
S.D 0.9 0 . 8 0.7 0.5 -
TABLE 27
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(yumol/vol) Mean 1-3 8-10 15-17
.1 A.G 1.3 1 . 0 0.7 — —
2 A.M 2 . 2 1 2,46 5.51 - —
3 D.M - 2.30 2.90 — -
4 H.W - 1 . 2 0 1.30 1.04 -
5 I.C 2.14 3.25 3.20 1.90 0.74
6 G.R - 0.94 1.04 1 . 1 0 -
Mean 1.60 1.50 2 . 0 0 1.30 0.74
S.D 0.60 1 . 0 0 1.80 0.40 -
TABLE 28
Copper in Urine, Medical I.V.N. Study
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No. Name Pre-Infusion 
^mol/vol )
Post-■Infusion Days
Mean 1-4 9-12 17-20 25-28
1 R.M 1.55 1.89
2 P.P - 0.58 0.46 0.9 1 . 0
3 E.I - 1.41 1.54 1.37 1.07
4 J.C 0.44 0.57 0.48 0.75 -
Mean 0.44 1.03 1.09 1 . 0 1 1.04
S.D - 0.46 0.63 0.26 0.04
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were similar, while on days 17-20 all three patients were 
above the normal range and they remained the same until days 
25-28.
Serum Copper
A) Crystalloid Study
Both groups, prior to operation, started within the normal 
range (with additive 18.3 1 3.5 yumol/1; without additive
21.4 - 3.7 yumol/1). Throughout the study both groups remained
within the normal range (Figure 23). There was no significant 
difference between the groups on each day of the study (Tables 
29 and 30). In both groups, on day 6 , out of ten patients, 
nine were within the normal range while one was above.
Caeruloplasmin, in both groups, was of similar concentration 
(with additive 299.1 - 119.9 mg/1; without additive 299.3
- 103.8 mg/1, which was within the normal range (150-450
mg/1). The concentrations remained the same throughout the 
study (Figure 26). There was no significant difference between
the groups on any day during the study.
B) Surgical I.V.N
Both anabolic and catabolic groups started with a normal 
copper concentration (Tables 31 and 32) and they stayed normal
until days 14-18. However, when the infusion was stopped,
the copper concentration had increased just above the normal
range (Figure 24). There was no significant difference between
the groups at any day during the study, but when the day
prior to operation was compared with the last day of infusion, 
in both groups, there was a significant increased (P less
than 0.01). In the anabolic group, out of five patients, 
four were above the normal range and one was within; while
in the catabolic group, all three patients were above the
74
TABLE 29
Copper in Serum, Patients with 4854 Infusion
No. Name Pre-op Days
1
Post-
3
op
5
1 /1 )
6
1 J.B 15.0 15.5 19.0 23.5 23.0
2 J.M 18.5 16.5 17.0 18.5 19.0
3 S.M 21.5 15.5 2 1 . 0 24.5 23.0
4 W.W 17.5 15.5 17.0 2 1 . 0 2 0 . 0
5 C.M 21.5 22.5 21.5 27.0 25.5
6 W.A 13.2 10.9 11.7 11.7 15.2
7 J.S 16.0 14.0 14.5 16.5 18.0
8 P.S 23.5 19.0 19.0 19.0 18.5
9 W.R 15.0 16.0 15.5 15.0 16.5
1 0 A.P 2 1 . 0 2 2 . 0 23.0 19.5 18.0
Mean 18.3 16.7 17.9 19.6 19.7
S.D 3.5 3.5 3. 5 4.6 3.2
TABLE 30
Copper in Serum, Patients without 4854 Infusion
No. Name Pre-op Days Post- (umol/1 )
1 3 5 6
1 M.M 25.0 23.5 24.0 22.5 23.0
2 A.C 17.0 18.0 2 2 . 0 18.0 19.0
3 W.L 27.0 27.5 27.5 26.5 26.0
4 J.M 18.5 17.5 16.5 19.5 20.5
5 M.M 18.0 18.5 17.0 19.5 18.0
6 H.S 17.5 17.0 19.5 2 2 . 0 2 2 . 0
7 J.M 23.5 25.5 23.0 2 1 . 0 2 1 . 0
8 T.C 25.5 21.5 2 0 . 0 2 0 . 0 2 0 . 0
9 R.M 2 1 . 0 16.0 17.0 18.5 18.0
1 0 H.S 2 1 . 0 14.0 13.5 16.0 15.5
Mean 21.4 19.9 2 0 . 0 20.4 20.3
S.D 3.7 4.4 4.2 2.9 3.0
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TABLE 29 IIA 
Caeruloplasmin, Patients with 4854 Infusion
No. Name Pre-op Days Post--op (mg/1 )
1 3 5 6
1 J.B 419 355 411 482 525
2 J.M 447 218 300 334 316
3 S.M 172 140 186 272 246
4 W.W 2 2 0 198 2 0 0 190 236
5 C.M - 380 - - 394
6 W.A - 70 46 1 1 0 230
7 J.S 250 148 230 148 250
8 P.S 226 226 198 244 198
9 W.R 270 2 0 0 236 160 250
1 0 A.P 390 310 382 306 254
Mean 299 225 243 250 290
S.D 104 98 1 1 0 115 99
TABLE 29 IIB
Caeruloplasmin, Patients without 4854 Infusion
No. Name Pre-op Days Post--op (mg/1 )
1 3 5 6
1 M.M 515 549 525 507 519
2 A.C 196 274 470 306 330
3 W.L 256 232 248 300 232
4 J.M 154 146 160 180 208
5 M.M 2 2 0 172 198 206 198
6 H.S 274 2 2 0 280 394 366
7 J.M 240 360 246 320 360
8 T.C 400 326 300 296 240
9 R.M 466 206 370 540 2 2 0
1 0 H.S 270 - - - -
Mean 299 276 311 339 297
S.D 1 2 0 123 1 2 2 1 2 2 106
TABLE 31
Copper in Serum, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(pmol/ 1  ) Mean 1-4 7-11 14-18
1 W.M 18.5 2 1 . 8 •mm 29.2
2 J.W 22.7 2 1 . 6 2 1 . 2 20.9 23.2
3 J.T - 21.9 2 0 . 0 - -
4 I.P 19.5 18.0 — 19.5 -
5 D.M 18.5 17.5 19.0 — 2 0 . 0
6 J.N 11.5 19.0 2 0 . 0 25.4 -
7 M.K 14.0 - 16.0 19.8 -
8 M.G 19.0 2 1 . 0 25.0 2 2 . 0 —
9 W.W 17.0 18.3 19.1 21.5 28.8
1 0 A.G 24.5 - 25.0 24.5 28.5
Mean 18.0 19.1 20.7 21.4 25.6
S.D 4.10 1.60 2.90 2.40 3.90
TABLE 32
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(jumol/ 1  ) Mean 1-4 7-11 14-18
1 A. G 15.0 14.0 19.5 — —
2 A.M - 23.5 23,9 26.5 -
3 D.M 13.5 2 1 . 0 24.5 - -
4 H.W 19.0 15.5 14.5 23.0 26.5
5 I.C 19.5 19.5 16.5 25.0 26.0
6 G.R - 16.0 23.5 23.8 2 2 . 0
Mean 16.5 18.0 19.8 24.3 24.7
S.D 3.00 3.60 4.20 1.50 2.30
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normal range.
C) Medical I.V.N
In this group, the patients started at a normal serum copper 
concentration (11.8 - 3.9 yumol/1) and then it rose steadily
during the study period (Figure 25). Copper concentration 
at the end of the study was above the normal range (28.1 
- 3.8 ^mol/1) (Table 33). Of three patients, two were above 
the normal range while one was at the upper limit of normal 
(23.0 yumol/1).
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TABLE 33
Copper in Serum, Medical I.V.N. Study
No. Name Pre-
Inf
Post-Infusion Days (yamol/l)
Stopping
ValueMean 1-4 7-11 14-18 21-24 28-32
1 R.M 13.5 23.5 - 17.0 - - 23.0
2 P.P - 12.5 16.5 2 0 . 0 2 2 . 0 17.0 29.0
3 E.I 15.5 16,7 19.3 21.7 23.0 27.1 32.3
4 J.C 6.5 - 13.5 14.0 - - -
Mean 1 1 . 8 17.6 16.4 18.2 22.5 2 2 . 1 28.1
S.D 3.9 4.5 2.4 2.9 0.5 5.1 3.8
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4.2.9 Discussion 
Copper Excretion
1) Crystalloid Study
Although copper losses by routes other than urine were not
measured, patients apparently retained about 96% of the copper 
infused, and the total mean percentage of urine copper excretion
was 3.4% during the study period. At the end of the study
there was no significant difference in copper excretion between 
the groups given the additive and the group without additive 
infusion.
2) Surgical and Medical I.V.N
The mean percentage of urinary copper excretion in the surgical 
anabolic group was 5.5 + 2.6%, while for the catabolic group
it was 9.9 +  6.0%, and for the medical patients it was 5.5
+ 2,6%. Copper excretion was higher in these patients compared 
to the crystalloid group, probably due to the presence of 
chelating agents such as amino-acids. Tyrala et al (1982) 
have shown in infants that copper excretion was increased 
when they were fed on amino-acids intravenously. Urinary 
copper excretion is increased during catabolic illness, and
copper behaves in a similar way to zinc.
Carr et al (19?5d reported increases in urine copper 
in children who were recovering from severe burning injury, 
the increase persisting for up to two months until healing 
occurred. This suggests that catabolism will increase the 
urine copper excretion.
In the present study, even although the urine copper 
excretion was increased, the total amount lost in urine never 
exceeded 2  yumol copper per day, therefore, this loss is unlikely
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to induce copper deficiency. The main route of copper excretion 
normally is via bile into faeces and only a small amount 
is excreted in urine. The amount of faecal excretion varies 
with the dietary input and this is the main homeostatic mechanism.
Serum Copper 
1) Crystalloid Study
Both groups started within the normal range. Serum copper 
concentration drops slightly after operation and then rises 
to within the normal range. This result was similar to that 
found by Hallbrook et al (1978). They studied forty-five 
patients subjected to surgical trauma. The patients were 
randomly distributed into two groups. One group received 
intravenously, a zinc and copper containing solution while 
the other group was without this additive. There was a fall 
of serum copper concentration in both groups after operation, 
and then it increased steadily. The fall was more pronounced 
in patients not receiving the additive. The duration of 
the present crystalloid study was not long enough to see 
a real change in copper concentration, since it is known 
that biochemical changes during copper deficiency develop
slowly. Mills (1979) has shown that when animals are deficient
in copper, the first change is in serum caeruloplasmin, then
in tissue, tyrosinase, cytochrome oxidase, superoxide dismutase
activity, and then clinical signs such as weight loss and
anaemia.
In this study, all the patients remained within the
normal range for serum copper. Serum caeruloplasmin showed
similar changes.
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B) Surgical and Medical I.V.N
Both groups did show a rise in serum copper concentration 
by the end of the study, when patients were either above 
the normal range or at the upper limit of the normal range. 
Also, there was a significant rise in caeruloplasmin level.
The expected levels of serum copper and caeruloplasmin for 
surgical patients of this type are at the upper limit of 
normal, since an increase in caeruloplasmin is an acute phase 
response to the stress or surgical trauma. Aronsen et al 
(1972) studied twenty-nine patients undergoing surgical operation 
and found that , the caeruloplasmin level starts increasing 
after the operation, and increases steadily for up to fourteen 
days.
The medical intravenous nutrition patients started with 
low normal serum copper levels, which is to be expected for 
patients not receiving any copper supplement (Hallbrook et 
al 1978). This group included patients with malabsorptive 
disease and possible history of increased faecal losses.
After a month or more, an intravenous nutrition with 20 
^mol (1.27 mg) copper per day additive, the average serum 
copper had risen to above the normal range, as expected in 
this sort of patient with a variety of stress and inflammatory
illness.
Conclusions
Various authors have reported copper deficiency during intravenous 
nutrition (Askari et al 1979; Lowry et al 1979). Many patients 
were treated by oral copper supplement ranging from 2-5 mg/day 
(31.5-78.7 yumol/day) of copper. Opinion as to the intravenous 
requirement is varied. The American Medical Association
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recommended 8-24 ^mol of copper intravenously, but from the 
present study it seems that 2 0  yumol copper per day can maintain 
copper levels in serum and can correct the acquired deficiency 
as in the medical cases. No evidence of clinical copper 
deficiency or biochemical signs were observed in any patients.
As with all other metals in individual cases where there 
is excessive faecal or fistula fluid loss, an increased supply
of intravenous copper may be required, but for the majority
of patients 20 jumol (1.27 mg) of copper is enough to maintain
serum copper levels. Serum copper or serum caeruloplasmin
seems a valid index of copper status.
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MANGANESE
4.3.1 Introduction
Manganese is widely distributed in nature but occurs only 
in trace amounts in biological materials, particularly in 
animal tissue. Even when the concentrations are highest 
in liver and kidney, manganese is present only in amounts 
of two to three parts per million, that is, microgram per 
gram dry weight. Despite these very small amounts, it is 
clear that manganese plays several important roles in the 
maintenance of biological functions. The earliest studies
were nutritional experiments which started about 1930 by 
McCollum, Elvehjem, Hart and others (Utter 1976), A few 
years later it was demonstrated that manganese prevented 
a skeletal abnormality in chickens. Since that time, manganese 
has been shown to be essential for many species of animals.
Possible manganese deficiency in man has been reported (Doisy 
1972).
Manganese is known to be a co-factor in a number of 
human enzymes, but no correlation between dietary intake 
and the activity of any of these enzymes has been demonstrated 
(Wenlock et al 1979),
4.3.2 Body Composition
The human body contains about 12-20 mg manganese. It is 
widely distributed in the body tissue and fluids. In the 
human, brain, kidney, pancreas and liver, in descending order, 
show higher manganese concentrations than other organs. 
Generally, higher manganese concentrations are seen in mitochondria 
compared to cytosol. Manganese concentration in blood and 
serum vary greatly. Whole blood contains about 9.0 pg/1 
(0,16 pmol/1), while serum contains about 0,5 pg/1 (0,009
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pmol/1). Serum manganese concentrations in normal humans 
have been variably reported, probably due to the contamination 
of blood during specimen collection (Versieck et al 1980).
4.3.3 Dietary Intake, Absorption and Excretion
The recommended dietary intake for manganese is 2.5-5 mg/day 
(41.5-91,0 pmol/day). The average daily intake in food is 
around 0.7-20 mg/day (10-300 pmol/day). Manganese content
of food varies greatly. The highest concentration is in nut
in
grain and cereals, while the lowest is^'dairy products, meat,
poultry, fish and sea-food. Relatively high concentrations 
of manganese were found in soluble ("Instant") coffee and
tea. This accounts for 10% of the total daily intake (McLeod 
et al 1972), During the first week of life, an infant's
manganese intake is low, 7 pg/day (0,13 pmol/day) producing 
a negative manganese balance, which is followed by a progress­
ively increasing intake of manganese from infancy to two
years, Despite this apparently diminished intake during 
early childhood, a relatively constant concentration of manganese 
is maintained in the liver throughout life.
The proportion absorbed is not certain but it has been 
estimated that a minimum of only 20 pg (0.36 pmol) must be
retained to prevent deficiency. The precise mechanisms of 
absorption of manganese from the gastrointestinal tract, 
and the status of specific blood carrier for manganese
is unclear at the present time. Although Cotzias et al (1960) 
proposed the existance of a specific manganese-carrying protein, 
called transmanganin, carrying one atom of manganese per 
molecule, there is not widespread agreement that manganese
is associated with a specific protein in blood.
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Absorbed manganese rapidly appears in the ‘ bile and is 
excreted almost exclusively in faeces. Smaller amounts are 
also excreted in other gastrointestinal secretions. Very 
little manganese is excreted in urine. The amount of faecal 
excretion varies with the dietary input, and this is the 
main homeostatic mechanism for maintaining balanced manganese 
tissue concentrations. This pathway is so effective that
manganese toxicity is rare and has only been identified after
chronic inhalation of large quantities of manganese dust
during industrial exposure,
4,3,4 Biochemical Importance
Even although the manganous ion is known to be an activator 
of many enzymes, it is not possible at present to correlate 
the activity of manganese-dependent enzymes and the degree 
of deficiency. However, the skeletal abnormalities produced 
in animals appear to be caused by defective function of two 
manganese-dependent enzymes, a polysaccharide polymerase
and galactotransferase, which are present in epiphyseal cartilege. 
These enzyme findings have not been made in man, but there 
have been some suggestions that an abnormality in manganese 
metabolism may be associated with the development of human 
mycopolysaccharidoses, which have many similar pathological 
features to the manganese deficiency state found in animals. 
Deficiency in animals has also been linked with sterility, 
possibly due to a reduced activity of mevalonate kinase, 
a manganese-dependent enzyme involved in cholesterol synthesis. 
A hypoglycaemic activity for manganese has also been suggested, 
but this is not proven.
Manganese seems to be intimately involved in the synthesis
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of protein, DNA and RNA, The DNA manganese complex was first 
reported in 1957. They concluded from its dissociation constant 
that manganese binds to DNA more strongly than do other metals.
Since minute quantities of manganese were detected during 
the isolation of RNA and DNA, it was suggested that manganese 
may bear a functional relationship to protein synthesis and 
the transmission of genetic information. However, direct 
evidence of the in vivo role of manganese in mammalian protein 
biosynthesis is still limited, although in vitro evidence 
indicates that manganese is involved in protein synthesis 
(Leach 1976). It is however, possible that other divalent 
ions, such as magnesium, may interchange with manganese, 
hence major effects of manganese depletion may only become 
evident when this interchange does not occur, for example, 
due to simultaneous depletion of other divalent cations.
4.3.5 Clinical Effects of Deficiency
Manganese deficiency has been well documented in animals 
and is characterised by growth impairment, skeletal deformity, 
reproductive and neuromuscular abnormalities. Other defects 
in carbohydrate metabolism have been observed with manganese 
deficiency. Many of the guinea-pigs with a congenital deficiency 
have short survival times and exhibit aplasia or hypoplasia 
of pancreatic tissue. Furthermore, these animals which survive 
to adult age exhibit abnormal tolerance to intravenously 
administered glucose (Prasad 1976),
The only postulated case of human manganese deficiency 
was reported by Doisy (1972). While studying vitamin K deficiency 
in a volunteer under metabolic ward conditions, it was noted 
that the patient had weight loss, transient dermatitis, occasional 
nausea and vomiting, changes in hair and beard colour, and
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slow growth of hair and beard. Protein synthesis seemed to 
be unaffected. The most striking finding was hypocholesterol- 
aemia. These findings were due to the inadvertent failure to 
add manganese to the purified diet mixture. Supporting evidence 
that this clinical picture resulted from manganese deficiency 
was obtained by duplicating the results in chicks fed a purified 
diet deficient in both vitamin K and manganese (Burch et al 
1975). These investigations suggest that manganese may be an 
essential trace element in man.
4.3.6 Biochemical Assessment of Mangarese Status
Ideally, techniques such as metabolic balance studies should 
be performed, but that is not practicable for large-scale studies. 
Therefore, measurement of manganese in serum has to be used 
as a convenient guide to manganese status. The normal range 
for manganese in serum is 7-27 nmol/1 (Table 6 ).
Studies performed in the early 1960s indicated that serum 
manganese may be increased following myocardial infarction or 
infectious hepatitis and it was proposed that manganese may 
be released from necrotic tissue. This observation has not 
been confirmed using careful sampling and analytical procedures.
4.3.7 Manganese in Intravenous Nutrition
Although the requirement for manganese has not been proven in 
man, the Food & Nutrition Board of the United States has recently 
provided guidelines for oral manganese 2.5-5 mg (46-91 pmol/day). 
An expert panel from the American Medical Association (1979) 
has recently suggested that for patients receiving intravenous 
nutrition, approximately 0.15-0.8 mg (3-13 pmol) manganese should 
be provided intravenously per day. For neonates, Shenkin et 
al (1978) suggested 0.3 pmol of manganese per kilogram per day 
intravenously.
88
In this study, 15 pmol (0.82 mg) per day of manganese 
was given intravenously to the patients.
4.2.8 Results of this Study 
Urine Manganese
A) Crystalloid Study
Urine manganese excretion in both groups was similar at the 
start and on post-operative day 1 (Tables 34 and 35). There 
was no significant difference between the groups on these days, 
but there was a significant increase (P less than 0.05) between 
the groups on post-operative days 2, 3 and 4. Also in the group 
given additive, when the day prior to operation was compared 
with post-operative days 2, 3 and 4, there was a significant 
increase (P less than 0.05) (Figure 27),
At the end of the study, in the group given the additive, 
the mean urine manganese excretion was 76.7 - 61.9 nmol/vol,
and out of seven patients, four were within the normal range 
and three were above, while in the group without additive, 
excretion was 25.6 1 13.1 nmol/1 and all eight patients were
within the normal range.
B) Surgical I.V.N
Both anabolic and catabolic surgical patients started within 
the normal range (51.0 1 36.0 nmol/vol) for anabolic patients,
and 19.0 t 13.0 nmol/1 for catabolic patients) (Tables 36 and 
37). There was no significant difference between the groups 
throughout the intravenous feeding period (Figure 28). Manganese 
excretion was above the normal range in both groups on days 
8-10 and 15-17. In the anabolic group on days 15-17, of nine 
patients, eight were above the normal range and one was within 
the range, while in the catabolic group, of four patients, two 
were within the normal range and two were above.
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TABLE 34
Manganese in Urine, Patients with 4854 Infusion
No. Name Pre-op
Days
Post-■op (nmol/vol)
1 2 3 4
1 J.B 24.0 1 2 . 0 24.0 99.0 2 1 0 . 0
2 J.M 2 1 . 0 60.0 60.0 70.0 40.0
3 S.M 8 . 0 5.0 1 2 . 0 45.0 74.0
4 W.W 7.0 13.0 19.0 24.0 48.0
5 C.M * * * * *
6 W.A 2 2 . 0 1 2 . 0 70.0 45.0 40.0
7 J.S * 1 0 . 0 25.0 27.0 *
B P.S 6 . 0 1 0 . 0 33.0 36.0 37.0
9 W.R 18.0 37.0 * * *
1 0 A.P 28.0 2 0 . 0 31.0 76.0 8 8 . 0
Mean 16.8 19.9 34.3 52.8 76.7
S.D 8 . 6 17,6 20.3 26.4 61.9
TABLE 35
Manganese in Urine, Patients without 4854 Infusion
No. Name Pre-op Days Post--op (nmol/vol)
1 2 3 4
1 M.M 6 . 0 1 1 . 0 1 0 . 0 2 1 . 0 13.0
2 A.C * 1 0 . 0 * 29.0 *
3 W.L 2 1 . 0 2 0 . 0 16.0 8 . 0 17.0
4 J.M 19.0 1 1 . 0 * 77.0 30.0
5 M.M 16.0 6 . 0 * * 28.0
6 H.S 2 1 . 0 25.0 4.0 28.0 49.0
7 J.M 27.0 8 . 0 14.0 18.0 1 0 . 0
8 T.C 15.0 59.0 17.0 * • 2 1 . 0
9 R.M * * 1 1 . 0 ■* 37.0
1 0 H.S * * * * *
Mean 25.6 18.8 1 2 . 0 30.2 25.6
S.D 2 2 . 8 17.5 4.8 24.2 13.1
* Urine contaminated
TABLE 36
Manganese in Urine, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1-3 8 - 1 0 15-17
1 W.M — 25.0 1 0 0  . 0 1 0 . 0 —
2 J.W - 141,0 134 .0 142 *0 2 1  . 0
3 J.T - 48 .0 74 .0 - -
4 I.P 2 0  . 0 53 .0 52 .0 67 .0 -
5 D.M 71 .0 90 .0 85 .0 117 .0 36 .0
6 J.N - 96 .0 162 . 0 2 0 1  . 0 -
7 M.K 910 141 .0 70 .0 62 . 0 -
8 M.G - - - 105 .0 -
9 W.W - 153 .0 1 0 2  . 0 194 .0 -
1 0 A.G 2 1  . 0 - - 116 . 0
Mean 51 .0 93 .0 97 .0 113 .0 29 .0
S.D 36 .0 49 .0 36 .0 62 . 0 1 1  . 0
TABLE 37
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1—3 8 - 1 0 15-17
1 A.G 1 0  . 0 30 .0 1 2 0  . 0 — —
2 A.M - 46 .0 64 .0 44 .0 -
3 D.M - 6 8  . 0 1 1 2  . 0 - -
4 H.W - 34 .0 140 .0 48 .0 -
5 I.C 28 . 0 33 .0 114 .0 95 .0 29.0
6 G.R - 82 . 0 1 0 1  . 0 160 , 0 -
Mean 19 .0 49 .0 109 .0 87.0 29.0
S.D 13 .0 2 1  . 0 25 .0 54.0 -
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C) Medical Ï.V.N
This group started with high manganese excretion (109.0 - 47.5 
nmol/vol) (Table 38). It was steadily increased and then became 
stable after days 9-12 (Figure 29). Although manganese excret­
ion was stable, it was above the normal range. All four patients 
were above the normal range through the intravenous feeding 
period.
Serum Manganese
A) Crystalloid Study
Both groups, prior to operation, started just above the normal 
range (with additive 14.2 - 7.0 nmol/1; without additive 8.9
- 4.4 nmol/1) (Tables 39 and 40). The patients without additive
remained constant throughout the study; when each post-operative 
day . was compared to the day prior to operation, there was no 
significant difference. The patients given additive show a
steady increase in the serum manganese concentration (Figure
30). In this group, there was a significant difference between 
the day prior to operation and post-operative day 5 (P less 
than 0 .0 1 ). Furthermore, when the groups were compared with 
one another on each particular day, there was a significant 
increase on day 3, and on day 5 (P less than 0.001). At the
end of the study, after cessation of intravenous manganese by 
day 6 , of ten patients, nine were within the normal range and 
only one was above. In the group not receiving intravenous 
manganese, of nine patients, six were within the normal range 
and three were sub-normal. In this group, two patients prior 
to operation started with sub-normal manganese serum concen­
trations and remained the same throughout the study.
TABLE 38
Manganese in Urine, Medical I.V.N. Study
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No. Name Pre-Infusion
(nmol/vol)
Post-Infusion Days
Mean 1-4 9-12 17-20 25-28
1 R.M - 175.0 183.0 - -
2 P.P - 480.0 60.0 75.0 105.0
3 E.I 157.0 179.0 143.0 160.0 207.0
4 J.C 62.0 6 8 . 0 79.0 115.0 —
Mean 109.5 225.5 116.2 116.7 156.0
S.D 47.5 153.5 49.3 34.7 51.0
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TABLE 39
Manganese in Serum, Patients with 4854 Infusion
No. Name Pre-op Days Post-■op {nmo 1 /1 )
1 3 5 6
1 J.B 15.0 15.0 25.0 25.0 17.0
2 J.M 13.0 7.0 2 0 . 0 15.0 6 . 0
3 S.M 16.0 1 1 . 0 27.0 36.0 31. Ô
4 W.W 9.0 1 1 . 0 15.0 17.0 1 0 . 0
5 C.M 13.0 13.0 2 2 . 0 31.0 2 0 . 0
6 W.A 13.0 1 2 . 0 19.0 18.0 18.0
7 J.S 9.0 1 0 . 0 17.0 27.0 18,0
8 P.S 5.0 5.0 1 1 . 0 17.0 1 1 . 0
9 W.R • 31.0 15.0 18.0 27.0 15.0
1 0 A.P 18.0 15.0 16.0 25.0 13.0
Mean 14.2 11.4 19.0 23.8 15.9
S.D 7.0 3.4 4.8 6.9 6 . 8
TABLE 40
Manganese in Serum, Patients without 4854 Infusion
No. Name Pre-op Days Post--op (nmol/1 )
1 3 5 6
1 M.M 2 0 . 0 18.0 18.0 16.0 16.0
2 A.C 1 0 . 0 1 1 . 0 6 . 0 6 . 0 6 . 0
3 W.L 7.0 2 . 0 7.0 9.0 4.0
4 J.M 5.0 5.0 5.0 5.0 5.0
5 M.M 1 2 . 0 13.0 7.0 1 1 . 0 23.0
6 H.S 7.0 5.0 4.0 7.0 9.0
7 J.M 7.0 7.0 5.0 2 . 0 -
8 T.C 7.0 8 . 0 4.0 1 2 . 0 9.0
9 R.M 6 . 0 4.0 4.0 7.0 7.0
1 0 H.S 8 . 0 1 0 . 0 9.0 9.0 1 0 . 0
Mean 8.9 8.3 6.9 8.4 9.9
S.D 4.4 4.8 4.2 3.9 6 . 1
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B) Surgical I.V.N
Both anabolic and catabolic groups prior to the infusion, started 
within the normal range ((17.0 -  10.0 nmol/1) for anabolic pat­
ients; 8.0 - 6.0 nmol/1 for catabolic patients) (Tables 41 and 
42). In the anabolic group, serum manganese concentrations 
steadily increased throughout the feeding period, but there 
was a fall in serum manganese concentrations when feeding was 
stopped. The catabolic group was similar, but there was a 
sheupp increase in manganese concentrations on days 1-4 (Figure
31). In both groups, when the day prior to operation was 
compared with the post-infusion day, there was a significant 
increase between the days on 7-11 and 14-18 (P less than 0.05), 
but there was no significant difference between the groups on 
any day during the study period. At the end of the study, on 
days 14-18, in the anabolic group all seven patients were above 
the normal range, and also in the catabolic group of four pat­
ients three were above the normal range while one was within 
the range.
C) Medical I.V.N
The medical patients prior to the infusion, started just above 
the normal range (33.7 - 15.5 nmol/1) (Table 43). Serum mangan­
ese concentrations remained steady to days 14-18, then increased 
until the end of the study (Figure 32). All four patients were 
above the normal range during the intravenous feeding period.
4.3.9 Discussion 
Urine Manganese 
Pi) Crystalloid Study
The calculated percentage of urinary excretion was 0.3 - 0.15% of 
the total infused dose of 60 umol (3.28 mg) of manganese.
TABLE 41
Manganese in Serum, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/1 ) Mean 1-4 7-11 14-18
1 W.M 25.0 44.0 17.0
2 J.W 5.0 31.0 34.0 34.0 1 0 . 0
3 J.T - 1 0 . 0 27.0 - -
4 I.P 17.0 24.0 - 32.0 -
5 D.M 31.0 24.0 25.0 - 2 0 . 0
6 J.N 13.0 29.0 42.0 44.0 -
7 M.K 27.0 - 69.0 1 0 2 . 0 -
8 M.G 7.0 40.0 16.0 33.0 -
9 W.W 25.0 35.0 38.0 41.0 24.0
1 0 A.G 13.0 - 27.0 47.0 25.0
Mean 17.0 27.0 36.0 48.0 19.0
S.D 1 0 . 0 9.0 15.0 25.0 6 .0 '
TABLE 42
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/1 ) Mean 1-4 7-11 14-18
1 A.G 2 . 0 13.0 18.0 —
2 A.M - 147.0 72.0 70.0 -
3 D.M 9.0 13.0 24.0 - —
4 H.W 15.0 14.0 27.0 24.0 14.0
5 I.C 5.0 1 0 . 0 2 1 . 0 31.0 33.0
6 G.R - 29.0 60.0 43.0 7.0
Mean 8 . 0 38.0 37.0 42.0 18.0
S.D 6 . 0 54.0 23.0 2 0 . 0 13.0
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TABLE 43
Manganese in Serum, Medical I.V.N. Study
No. Name Pre-
Inf
Post-Infusion Days (nmol/1 )
Mean 1-4 7-11 14-18 21-24 28-32
Stopping
Value
1 R.M 53.0 60.0 - 2 2 . 0 - - -
2 P.P 27.0 32.0 24.0 33.0 17.0
3 E.I 33.0 55.0 51.0 49.0 1 2 1 . 0 169.0 80.0
4 J.C 15.0 25.0 33.0 - - -
Mean 33.7 47.3 36.0 32.0 77.0 93.0 80.0
S.D 15.5 14,5 1 1 . 0 10.7 44.0 76.0 -
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Thus, about 99% of infused manganese is retained by the patients. 
The main route of manganese output is via faeces. However, 
in these patients, faecal output was not measured, since 
faecal production was minimal. This suggests that the retention 
of manganese in these patients is very high.
B) Surgical and Medical I.V.N
The surgical anabolic patients had an average manganese output 
of 0.3 - 0.13%, retaining therefore about 99% of infused
dose over the study period. Catabolic patients excreted 
0 . 1  - 0 .2 % retaining the same amount as that of anabolic
patients. Whereas the medical group excreted about 1.0 
“0.28% of their infused manganese. This suggests that the 
urinary manganese excretion in all these patients is very 
low indeed.
Serum
A) Crystalloid Study
The patients from both groups prior to operation started 
within the normal range of serum manganese. The level drops 
after the operation as a response to stress or trauma. In
the group without additive, the serum manganese concentration 
was constant, which was at the lower limit of the normal 
range throughout the study period, while in the group given
additive serum manganese increases considerably until day 
5, but the serum concentration fell substantially within 
twenty-four hours of stopping the infusion. Even although 
serum manganese levels were at the upper limit of the normal
range, there were no clinical or biochemical signs of toxicity.
B) Surgical and Medical I.V.N
The anabolic and the catabolic patients started within the 
normal range, and values rose throughout the study to above
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the normal•range in virtually all surgical intravenous nutrition 
patients. After cessation of intravenous manganese, the
serum manganese level drops considerably.
The medical patients started above the normal range 
and remained the same throughout the study. Even although 
the serum manganese levels were high, there were no clinical 
or biochemical signs of toxicity. In earlier studies, Addamel^ 
was used, providing 60 pmol (328 mg) of manganese per day. 
In these patients, manganese excretion was as high as about 
649 nmol/volume; even then, in these patients there was no 
evidence of manganese toxicity.
Conclusions
From all these different studies it seems that manganese 
requirement for man is very low indeed. In this trial, manganese 
supply was at the upper limit of the recommended allowance, 
and 15 umol/day (0.82 mg) provided intravenously during this 
study, is too high for the majority of the patients. Probably 
only half of this amount, that is 7.5 pmol/day (0.41 mg), 
would be sufficient to maintain serum manganese concentrations 
within the normal range. The American Medical Association 
has suggested that patients receiving intravenous nutrition 
should receive 3-13 pmol/day.
One author has suggested that poor bone growth and healing 
is present in orthopaedic patients, who apparently have no 
detectable manganese or copper in serum (Saltman 1981).
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Comparison of manganese excretion in two groups of 
ten patients, with 4854 and without 4854 infusion.
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Comparison of serum manganese concentrations in two 
groups of ten patients, with 4854 and without 4854 
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Serum manganese concentrations in ten anabolic patients 
and six catabolic patients receiving 4854 infusion.
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Excretion of manganese in four medical patients 
receiving 4854 infusion.
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CHROMIUM
4.4.1 Introduction
Chromium is found in varying concentrations in air, water, 
soil and in most biological tissue. Its existence has been
known for almost two centuries, and for most of the time
it was thought only to be harmful. However, its role as 
an essential element for normal growth and development in 
animals has been well documented in the past two decades,
and its essentiality for humans has been proposed recently.
Chromium was shown to be an essential trace element 
by Mertz and Schwarz (1979). They observed that rats fed 
with stock laboratory diets had impaired tolerance to a glucose 
load. This intolerance was reversed by an insulin potentiating 
factor which was present in brewer's yeast, meat and other 
foods. An organic chromium complex, of uncertain structure, 
known as the glucose tolerance factor (GTF) appears to act 
in a complex with insulin to facilitate the entry of glucose 
into cells. The essentiality of chromium for humans was 
subsequently demonstrated in 1975 (jeejeebhoy et al 1975; 
Freund et al 1979), during prolonged intravenous feeding.
Chromium appears to act to potentiate the effects of insulin 
and therefore it has influence on carbohydrate lipid and 
protein metabolism.
4.4.2 Body Composition
The chromium concentration in different tissue have been 
reported to vary from less than one part per billion, that 
is microgram per litre, to several parts per million, that 
is milligrams per litre, wet weight (Mertz 1969), but this 
variation is partially attributable to discrepancies between
1 0 0
different analytical techniques. Approximately half of
the naturally occuring chromium in liver has been reported 
to be concentrated in the nuclear fraction. With recent 
advances in atomic absorption techniques, it now appears 
that the previous published estimates of serum chromium concen­
trations were inaccurate. The total amount of chromium
thought to be present in serum is around 2  nmol/1 , that is 
0 . 1  jig/1 , which is near the detection limit of most commonly 
available methods. These values are lower by at least an
order of magnitude than previous estimates (Versieck et al
1980). The concentration in normal urine is however, somewhat 
higher, around 10 nmol/1 (6-43 nmol/24 hours) (Table 5).
4.4.3 Dietery Intake, Absorption and Excretion
The recommended dietary intake for chromiuni is around 50- 
200 jig/day (0.96-3.85 pmol). Minimum daily requirement
for chromium is around 50 pg/day (0.96 pmol). There are 
few foodstuffs with appreciable amounts of chromium. It 
is possible that diets adequate in energy and protein are 
not necessarily optimal for chromium. Spices, brewer's
yeast, liver and kidney are considered good sources but only 
small quantities are present in fish, vegetables and fruit. 
Western diet, where a high proportion of. energy needs are 
met by refined carbohydrate, have lower total amounts of 
chromium than diets in other parts of the world.
Little work has been done on the intestinal absorption 
of chromium in man. Inorganic trivalent chromium salts are 
poorly absorbed by man and animals. Chromâtes are better 
absorbed but the preferred valency state for chromium in 
physiological conditions is Cr3+ , and it is likely that any 
chromâtes present in the diet are reduced in the gastro i-
1 0 1
intestinal tract from Cr to Cr^^. Absorption of ^^Cr labelled
chromic chloride is limited to approximately 0.5% (Hambidge
1981). In vitro investigations using the ..rat intestine suggest
that Cr^^ may enter into the mucosal cell by a process of
either simple or facilitated diffusion and subsequently be
transported across the serosal surface by a more specific
mechanism (Mertz et al 1971). The rate of absorption may
be decreased by the presence of other metals and increased
by various chelating agents. In contrast to the very restricted
3+absorption of inorganic Cr , 10-25% of chromium has been
found to be absorbed from organic complexes in brewer's yeast.
It seems clear that at least two forms of chromium circulate 
in the plasma compartment. Some chromium is bound to trans­
ferrin in the beta-globulin fraction and is thought to be 
trivalent chromium. The other form is presumably GTF
bound chromium, but definite studies on this point have yet
to be done. There is ample evidence regarding dietary require­
ment for chromium, but little or no evidence regarding the 
necessity for certain species of chromium in diet. However, 
inorganic compounds must be converted to the biologically
active form to function in vivo.
The major excretory route for chromium is by the kidney, 
and urine contains at least 80% of all excreted chromium. 
A small percentage is excreted via the intestine into faeces, 
which contains all unabsorbed chromium. Urinary chromium
is derived from a relatively small fraction of the plasma 
chromium which is dialysable. Until the late 1970s, urine 
chromium excretion rates were thought to average from 5-10 
ug daily in adults. However, as with plasma, recent advances 
in analytical techniques have led to a downward revision
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of this figure. Hence, calculated requirements for intestinal 
absorption of chromium have decreased proportionately, and 
it now appears that man may need less than 1 pg/day to achieve 
chromium balance ; and normal urinary excretion is around
10 nmol/1 (0.5 pg/1) (Table 5).
4.4.4 Biochemical Importance
Various studies have shown some response to chromium in certain
enzyme systems and pathways (Mertz 1969). Mathur and Doisy
(1972) noted a marked shift in the hepatic intracellular
distribution of chromium in rats under conditions of increased
51protein synthesis. The Cr label shifted from nucleus to
the cytoplasm in these experiments. The place of chromium
in human nutrition remains uncertain. There is no known
role for chromium other than in the form of glucose tolerance 
factor. Oral administration of chromium complex which is
present in brewer's yeast and is known as the glucose tolerance 
factor has been shown to improve carbohydrate metabolism
in diabetic subjects. When taken by normal persons, it
can increase the proportion of cholesterol in high density 
lipoproteins (Mertz 1980; Riales et al 1981). The biochemical 
mechanisms underlying these effects are not understood.
Variable reports have been made during clinical trials of 
inorganic chromium supplements given to diabetic patients 
and it seems that the complex which occurs naturally in yeast 
is required for the most efficient intestinal absorption
of chromium. A major problem in all clinical studies is 
the difficulty of reliable determination of chromium in bio­
logical material and of the biologically active glucose tolerance 
factor. Most previous published estimates of chromium concen­
trations are inaccurate.
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4.4.5 Clinical Effects of Deficiency
In experimental animals, diets low in chromium result in 
impaired growth, and reduced life-span with disturbances 
of glucose, lipid and protein metabolism. Rats deprived
of adequate protein and of chromium, develop corneal lesions. 
The best evidence for the occurrence of human chromium deficiency 
states has been derived from the results of therapeutic trials 
of dietary supplementation with chromium. Subjects selected 
for these studies were chosen on the basis of impaired glucose 
tolerance, rather than biochemical evidence of chromium depletion. 
Most of the subjects improved. Therefore, the potential
clinical importance of these findings is considerable (Hambidge 
1981). A severe impairment of glucose tolerance, found in 
malnourished infants improves upon supplementation of the 
diet with 250 jug (4.8 pmol) of inorganic chromium per day 
(Saner 1980). Chromium deficiency has now been described
in patients receiving prolonged parenteral nutrition. The
first case described by Jeejeebhoy et al (1977) was a woman 
who developed unexpected weight loss and peripheral neuropathy 
after three and a half years of previously successful intravenous 
nutrition. She had marked glucose intolerance, resistant
to insulin therapy. A negative chromium balance was found 
and low values of chromium demonstrated in whole blood and 
hair, relative to control samples. Infusion of inorganic
chromium (150 pg/day or 4.8 jumol) for two weeks, resulted 
in clinical improvement, a reduction in plasma glucose levels 
with improvement in glucose tolerance and reduced requirement 
for insulin. Positive nitrogen balance was restored with
body weight gain, and the peripheral neuropathy recovered 
after a few months of chromium therapy. In a later study,
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Freund et .al (1979) reported that a 45 year old woman who 
had been maintained for five months by intravenous nutrition 
after complete bowel resection, developed severe glucose 
intolerance, culminating in a hyperglycaemic hyperosmolar 
nonketotic coma. This patient lost body weight despite
adequate energy input and exhibited a confusional state re­
sembling hepatic encephalopathy. However, infusion of 150
pg chromium/day (2 . 8 8  pmol) was given and rapid improvement 
was observed. Within three to four days, glucose levels
in blood returned to normal without the need of exogenous 
insulin. This patient also showed restoration of body weight 
on the same level of energy and protein intake as had been 
offered previously.
4.4.6 Biochemical Assessment of Chromium Status
The establishment of reliable and preferably simple, laboratory 
assays and criteria for the assessment of chromium nutrition, 
would obviously facilitate the detection and confirmation 
of chromium deficiency states. Unfortunately, no simple
assay of proven validity is yet available and, even in the 
fully equipped research laboratory, major problems persist.
In the past, one outstanding problem has been the lack 
of analytical instrumentation and techniques of sufficient 
sensitivity and precision to allow accurate quantitative 
analysis of chromium concentrations of few parts per billion 
(ppb), that is micrograms per litre (pg/1 ) or less in biological 
materials. However, there has been very substantial progress 
recently in the development of more sensitive and sophisticated 
analytical systems, which have proved useful for the determin­
ation of chromium in biological samples. These include
neutron activation analysis, stable isotope dilution techniques
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and graphite furnace atomic absorption spectrophotometry 
with improved background correction systems.
The definition of chromium deficiency cannot rely solely 
upon determination of chromium in body tissue or fluids. 
The lowering of plasma insulin response to a glucose load, 
and /or improvement of glucose tolerance after a period of 
chromium supplementation is the most convincing evidence 
of prior chromium deficiency state. In normal individuals, 
there also should be a sharp increment in plasma and urine 
chromium levels within 30-120 minutes of a glucose load. 
Failure to observe this change suggests tissue deficiency 
of the glucose tolerance factor. Substantial GTF biological 
activity has been detected in hair follicle s and there are 
some indications that measurement of the chromium content 
of hair can give a useful indication of body chromium status 
(Hambidge 1981). However, caution is necessary in interpreting 
these results, since in general, hair analysis probably provide 
only a rather crude index of trace element nutritional status.
Urine contains most of the chromium excreted by the 
body and the rate of urinary chromium excretion reflects 
in part the quantity of chromium in the diet. Furthermore, 
the majority of chromium present in the urine may be derived 
from biologically active components of plasma chromium. 
Therefore, it seems that measurement of increases in chromiun 
in serum and urine, after glucose loads, has to be used as 
the only practicable guide to chromium status.
4.4.7 Chromium in Intravenous Nutrition
Acute chromium deficiency has been described by two different 
groups, in patients receiving long-term parenteral nutrition. 
The cases are described in Section 4.4.5. This illustrates
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the need to consider chromium requirement during intravenous 
nutrition. The use of 50% glucose as the sole energy source, 
may accentuate underlying deficiency by promoting urinary 
excretion of chromium. The American Medical Association 
recommended input is 15-20 pg Cr/day (0.28-0.38 pmol/day)
during intravenous feeding. However, it is likely that
the naturally occuring level of chromium, as a contaminant 
in amino-acid, carbohydrate and lipid solutions, is a consider­
able proportion of this requirement. Since urine chromium 
is increased during infusion of carbohydrates and any excess 
intravenous chromium will be rapidly excreted by the kidney, 
it is probably necessary to make some addition of chromium 
in intravenous feeding.
In this study, 0.4 pmol/day (20,8 pg/day) chromium was 
given intravenously to the patients.
4.4.8 Results of this Study 
Urine Chromium
A) Crystalloid Study
Urine chromium excretion in both groups was within the normal 
range at the start of the study (22.1 - 13.9 nmol/volume
in the group with additive and 19,3 - 9.9 mmol/volume for
the group without additive). (Tables 44 and 45). There
was a significant difference (P less than 0.05) between the
groups on post-operative days 1, 2, 3 and 4. Also, in the
group given additive, when the day prior to operation was
compared with post-operative days 1, 2, 3 and 4, there was
a significant increase (P less than 0.05) (Figure 33). 
The group without additive remained constant throughout 
the study. At the end of the study, in the group with additive, 
the mean urine chromium excretion was 127,4 i 30.6 nmol/volume)
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TABLE 44
Chromium in Urine, Patients with 4854 Infusion
No. Name Pre—op
Days
Post-op (nmol/vol)
1 2 3 4
1 J.B 50.0 70.0 1 0 0 . 0 140.0 1 2 0 . 0
2 J.M 2 0 . 0 70.0 1 2 0 . 0 1 2 0 . 0 1 0 0 . 0
3 S.M 1 1 . 0 130.0 1 2 0 . 0 1 1 0 . 0 140.0
4 w.w 1 1 . 0 45.0 83.0 1 0 0 . 0 1 0 0 . 0
5 C.M * * * * *
6 W.A 19.0 45.0 81.0 106.0 1 2 2 . 0
7 J.S 1 1 . 0 6 6 . 0 131.0 133.0 140.0
8 P.S 17.0 1 0 0 . 0 1 0 1 . 0 134.0 185.0
9 W.R 19.0 58.0 8 6 . 0 83.0 87.0
1 0 A.P 41.0 87.0 128.0 239.0 153.0
Mean 2 2 . 1 74.6 105.6 129.4 127.4
S.D 13.9 27.4 19.7 44.9 30.6
TABLE 45
Chromium in Urine, Patients without 4854 Infusion
No. Name Pre-op Days Post-op (nmo1 /vol)
1 2 3 4
1 M.M 6 . 0 1 1 0 . 0 47.0 60.0 44.0
2 A.C 2 0 . 0 70.0 30.0 30.0 40.0
3 W.L 1 2 . 0 5.0 5.0 31.0 9.0
4 J.M 13.0 27.0 37.0 56.0 53.0
5 M.M 18.0 14.0 42.0 33.0 18.0
6 H.S 1 2 . 0 2 1 . 0 1 2 . 0 28.0 26.0
7 J.M 41.0 1 2 . 0 23.0 45.0 18.0
8 T.C 25.0 31.0 * 38.0 25.0
9 R.M 27.0 * 45.0 * 43.0
1 0 H.S 19.0 28.0 55.0 41.0 30.0
Mean 19.3 35.3 32.9 40.2 30,6
S.D 9.9 33.6 16.8 11.5 14.0
* Urine contaminated
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and all nine patients were above the normal range, while 
in the group without additive, excretion was 30.6 + 14.0
nmol/volume, and of ten patients, nine were within the normal 
range and one was above.
B) Surgical I.V.N
Both anabolic and catabolic surgical patients started above 
the normal range (185.0 - 114.0 nmol/volume for anabolic
"f*
patients and 141.0 - 138.0 nmol/volume for catabolic patients).
(Tables 46 and 47). There was no significant difference
between the groups, and urine chromium excretion was above 
the normal range throughout the intravenous feeding period.
At the end of the study, in both groups on days 15-17, all
patients were above the normal range (Figure 34).
•C) Medical I.V.N
This group started with a high chromium excretion (480
- 369.0 nmol/volume) (Table 48). It was constant throughout 
the intravenous feeding period. Although chromium excretion 
was stable, it was above the normal range. All four patients 
were above the normal range during the study period.
Serum Chromium
A) Crystalloid Study
Both 'groups prior to operation started with barely detectable 
levels (with additive 5.2 ~ 3.3 nmol/1; without additive
5.2 - 2.2 nmol/1 (Tables 49 and 50). The patients without
additive remained constant throughout the study at very low 
levels. However, the patients with additive showed a sharp 
increase in serum chromium concentrations (Figure 36) after 
post-operative day 1. In this group there was a significant 
increase between the day prior to the operation and post­
operative days 3, 5 and 6  (P less than 0.01). Furthermore,
TABLE 46
Chromium in Urine, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1-3 8 - 1 0 15-17
1 W.M 300.0 280.0 450.0 —
2 J.W - 169.0 312.0 271.0 61.0
3 J.T - 2 2 2 . 0 330.0 - -
4 I.P 157.0 298.0 268.0 418.0 -
5 D.M 314.0 282.0 428,0 294.0 -
6 J.N - 255.0 247.0 309.0 -
7 M.K 224.0 403.0 405.0 407.0 —
8 M.G 40.0 146.0 193.0 355.0 -
9 W.W. - 265.0 405.0 428.0 -
1 0 A. G 76.0 - - 253.0 -
Mean 185.0 258.0 338.0 342.0 61.0
S.D 114.0 75.0 90.0 70,0 —
TABLE 47
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1-3 8 - 1 0 15-17
1 A.G 300.0 280.0 450.0 - -
2 A.M 54.0 62.0 336.0 331.0 —
3 D.M - 182.0 368.0 - -
4 H.W - 288.0 287.0 365.0 -
5 I.C 6 8 . 0 176.0 345.0 338.0 -
6 G.R - 528.0 565.0 478.0 -
Mean 141.0 253.0 392.0 378.0 -
S.D 138.0 158.0 1 0 0 . 0 6 8 . 0 -
TABLE 48
Chromium in Urine, Medical I.V.N. Study
1 1 0
No, Name Pre-Infusion Post-■Infusion Days
(nmol/v61) Mean 1-4 9-12 17-20 25-28
1 R.M - 305.0 493.0 - —
2 P.P — 300.0 313.0 355.0 355.0
3 E.I 1 1 1 . 0 378.0 436.0 422.0 356.0
4 J.C 849.0 720,0 659.0 778.0 -
Mean 480.0 426.0 475.0 518.0 356.0
S.D 369.0 173.0 124.0 186.0 0.5
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TABLE 49
Chromium in Serum, Patients with 4854 Infusion
No, Name Pre-op Days Post-■op (nmo1 /1 )
1 3 5 6
1 J.B 8 . 0 1 1 . 0 74.0 81.0 1 0 0 . 0
2 J.M 4.0 4.0 75.0 107.0 70.0
3 S.M 7.0 14.0 97.0 156.0 1 2 0 . 0
4 W.W 7.0 6 . 0 65.0 96.0 67.0
5 C.M. 2 . 0 2 . 0 61.0 96.0 58.0
6 W.A 2 . 0 4.0 67.0 90.0 87.0
7 J.S 5.0 5.0 69.0 1 1 0 . 0 87.0
8 P.S 2 . 0 5.0 91.0 138.0 95.0
9 W.R 1 2 . 0 1 0 . 0 108.0 1 2 1 . 0 1 0 1 , 0
1 0 A.P 3.0 4.0 81.0 125.0 79.0
Mean 5.2 6.5 78.8 1 1 2 . 0 86.4
S.D 3.3 3.8 15,3 23.2 18.6
TABLE 50
Chromium in Serum, Patients without 4854 Infusion
No. Name Pre-op Days Post--op (nmol/1 )
1 3 5 6
1 M.M 4.0 1 0 . 0 15.0 14.0 16.0
2 A.C 2 . 0 2 . 0 5.0 3.0 4.0
3 W.L 5.0 5.0 9.0 6 . 0 6 . 0
4 J.M 7.0 1 1 . 0 1 1 . 0 6 . 0 1 0 . 0
5 M.M 6 . 0 6 . 0 7.0 2 . 0 3.0
6 H.S 2 . 0 2 . 0 2 . 0 6 . 0 3.0
7 J.M 6 . 0 1 2 . 0 8 . 0 1 0 , 0 1 0 . 0
8 T.C 8 . 0 9.0 7.0 1 1 . 0 7.0
9 R.M 4.0 8 . 0 8 , 0 1 1 . 0 8 . 0
1 0 H.S 8 . 0 7.0 6 . 0 1 2 . 0 1 1 . 0
Mean 5.2 7.2 7.8 8 . 1 7.8
S.D 2 . 2 3.5 3.5 4.0 4.1
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when the groups were compared with one another on post-operative 
days 3, 5 and 6 , there was a significant difference (P less
than 0.01). Although at the end of the study, after cessation
of intravenous chromium on day 5, by day 6 , serum chromium 
concentrations fell. All ten patients were still above the
normal range, while in the group not given intravenous chromium, 
serum chromium remained unchanged.
B) Surgical I.V.N
Both anabolic and catabolic groups prior to infusion, started 
above the normal range (34.0 - 21.0 nmol/1 for anabolic patients 
and 14.0 i 1 1 . 0  nmol/ 1  for catabolic patients) (Tables 51
and 52). In both groups, serum chromium concentrations
steadily increased during the study, but there was a fall 
in serum chromium concentration when provision of intravenous 
chromium was stopped. There was a sharp increase in serum
chromium concentrations on days 14-18 in the anabolic group, 
while the catabolic group values on days 14-18 remained similar 
to those on days 7-11 (Figure 37). In both groups, when
the day prior to infusion was compared with post-infusion 
days, there was a significant increase through the infusion 
period (P less than 0.05). Also, there was a significant 
difference between the groups on days 14-18 (P less than 
0.05). The study ended on days 14-18. Measurements made 
at varying times thereafter, showed that all patients were 
above the normal range. (Seven patients in the anabolic
group and four patients in the catabolic group).
C) Medical I.V.N
The medical patients prior to infusion, started with high 
serum chromium concentrations (29,0 i 11.0 nmol/1) (Table 
53). Serum chromium concentrations increased steadily through-
TABLE 51
Chromium in Serum, Surgical I.V.N. Study 
ANABOLIC GROUP
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No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/1 ) Mean 1-4 7-11 14-18
1 W.M — 76.0 129.0 — 89.0
2 J.W 1 2 . 0 58.0 84.0 106.0 64.0
3 J.T - 6 . 0 62.0 - -
4 I.P 1 1 . 0 82.0 - 140.0 -
5 D.M 40.0 49.0 74.0 — 133.0
6 J.N 31.0 - 204.0 239.0 —
7 M.K 34.0 - 132.0 219.0 -
8 M.G 27.0 75.0 44.0 162.0 -
9 W.W. 78.0 84.0 97.0 1 1 0 . 0 76.0
1 0 A.G 42.0 - 146.0 350.0 127.0
Mean 34.0 61.0 108.0 189.0 98.0
S.D 2 1 . 0 28.0 50.0 87.0 31.0
TABLE 52
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/1 ) Mean 1-4 7-11 14-18
1 A,G 1 0 . 0 30.0 50.0 _ —
2 A.M - 2 2 . 0 72.0 70.0 -
3 D.M 31.0 37.0 113.0 — —
4 H.W 1 1 . 0 33.0 60.0 105.0 43.0
5 I.C 5.0 24.0 39.0 73.0 62.0
6 G.R - 13.0 113.0 89.0 -
Mean 14.0 27.0 75.0 84.0 53.0
S.D 1 1 . 0 9.0 32.0 16.0 13.0
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TABLE 53
Chromium in Serum, Medical I.V.N. Study
No, Name Pre-
Tr^’P  ... ____
Post--Infusion Days (nmol/I)
Stopping
Value
xni
Mean 1-4 7-11 14-18 21-24 28-32
1 R.M 14.0 35.0 - 61.0 - — -
2 P.P — 78.0 8 6 . 0 116.0 126.0 87.0 -
3 E.I 39.0 6 6 . 0 105.0 132.0 137.0 159.0 76.0
4 J.C 35.0 "" 94.0 1 2 2 . 0 - - -
Mean 29.0 60.0 95.0 108.0 132.0 123.0 76.0
S.D 1 1 . 0 18.0 7.8 28.0 6 . 0 36.0 -
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out the intravenous feeding period (Figure 38). After cessation 
of intravenous chromium infusion, serum chromium concentrations 
fell rapidly. All four patients were above the normal range 
throughout the study period.
116
4.4.9 Discussion 
Chromium Excretion
A) Crystalloid Study
Although chromium losses by routes other than urine were 
not measured, the calculated percentage of urinary excretion 
was 27.3 - 6.1%, of the total infused dose of 1.6 pmol chromium 
over the study period, patients apparently retained about 
72% of the infused chromium. In the group with additive,
the urinary excretion was much higher over four days. Also 
in the unsupplemented group, urine excretion increased slightly 
on post-operative days 2 and 3, indicating a small metabolic 
response to the operation, or possibly to the provision of 
intravenous glucose solution enhancing the chromium output.
B) Surgical and Medical I.V.N
In the surgical group, the anabolic patients had an average 
chromium output of 77.0 “ 14.8%, retaining therefore about
23% of the infused dose, whereas the more catabolic surgical 
patients excreted some 83.6 - 25.3% of the infused chromium,
retaining about 16% only of the chromium infusion. Urine 
chromium excretion was high indeed in the medical patients, 
about 115.5%. It should be considered that chromium present 
in (4854) trace element additive, is hexavalent whereas the 
biologically essential species or form of chromium is generally 
considered to be trivalent. The extent to which the hexavalent
chromium is converted to trivalent chromium, either in a 
three-litre bag or in vivo, is not known.
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Serum Chromium
A) Crystalloid Study
The patients from both groups prior to operation, started 
at low levels of serum chromium. In the group without additive, 
the serum chromium concentrations remained barely detectable, 
while there was a substantial increase in serum chromium 
concentrations in the group with additive, after post-operative 
day 1, with levels as high as 150 nmol/1 (after four days) 
being achieved. Serum chromium concentrations fell rapidly 
within twenty-four hours after cessation of the chromium 
infusion.
B) Surgical and Medical I.V.N
The anabolic and the catabolic surgical patients had detectable 
levels of serum chromium, which increased steadily through­
out the study. After cessation of the intravenous chromium, 
the serum chromium level dropped rapidly. The high serum
chromium concentrations suggest that the increased urinary 
chromium losses resulted from the rise in serum chromium 
concentrations.
The medical patients had clearly measurable serum chromium 
concentrations, which increased throughout the intravenous 
feeding period. Even although chromium concentrations were 
high in all these different patients, there were no clinical 
signs of toxicity.
Conclusions
From the three studies, it seems that the chromium requirement 
for man is very low indeed. It seems likely that chromium 
provided in (4854) trace metal additive at 0.4 pmol/day (400 
nmol/day) is excessive for the majority of the patients, 
especially since it adds to the chromium present in the amino-
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acid solutions, as a contaminant. Therefore, probably only 
half of the amount, that is 0 . 2  pmol/day ( 2 0 0  nmol/day) would 
be sufficient to maintain serum chromium concentrations during 
intravenous nutrition. The American Medical Association
recommendation for adult patients receiving intravenous nutrition 
is 280-380 nmol/day (15-20 pg/day) of chromium.
In this study, for trials, initially 400 nmol/day was 
used, which was at the upper end of the AMA range. It 
is now suggested that 2 0 0  nmol/day is adequate.
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Figure 33
Comparison of chromium excretion in two groups of ten 
patients, with 4854 and without 4854 infusion.
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Figure 36
Comparison of serum chromium concentrations in two groups
of ten patients, with 4854 and without 4854 infusion.
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Figure 34
Excretion of chromium in ten anabolic patients and six 
catabolic patients receiving 4854 infusion.
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Figure 37
Serum chromium concentrations in ten anabolic patients 
and six catabolic patients, receiving 4854 infusion.
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Excretion of chromium in four medical patients receiving 
4854 infusion.
150
nmol/l.
c
H
R
0  100
M
I
U
M
P 
E 
R
L 
I
T
R 
E
50
10
SERUM CHROMIUM LEVELS "MEDICAL" GROUP
/
REFERENCE RANGE 
<10 nmol/l.
PRE INF. 1-4 7-11 14-18 21-24 28-32 POST INF.
POST INFUSION DAY
Figure 38
Serum chromium concentrations in four medical patients
receiving 4854 infusion.
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SELENIUM
4.5.1 Introduction
Selenium has been shown to be an essential element for several 
animal species. Selenium occurs in all cells and tissues
of the animal body in concentrations which vary with the 
level and chemical form of selenium in the diet. The economic 
importance of selenium in the nutrition of farm livestock
is well appreciated and has prompted basic studies of selenium
biochemistry (Underwood 1977), The essential role of selenium 
in human nutrition is only recently recognised (Young 1981).
Previously, more interest was expressed in the potential 
toxic effect of this metalloid.
Selenium has been shown to be an essential constituent 
of erythrocyte glutathione preoxidase in several species, 
and such an enzyme is known to be present in human red cells 
and plasma. Dietary deficiency of selenium (together with
vitamin E deficiency) induces muscular dystrophy (ruminants), 
pancreatic degeneration and increased capillary permeability 
(poultry) and liver necrosis (rats).
Chinese investigators have shown that selenium deficiency
is one of the principal factors responsible for Keshan disease,
a cardiomyopathy which affects persons (mainly children and 
young women) living in rural areas of a selenium-deficient 
zone in China.
4.5.2 Body Composition
The whole body content of selenium is in the region of 2- 
10 mg (25-125 pmol/1). By analogy with animal studies,
human liver and kidney will contain most selenium with lesser 
amounts in skeletal muscle, skin and bone. The concentration 
of selenium in blood is highly responsive to the changes
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in selenium levels in the diet over a wide range. The selenium 
levels in whole blood from 210 male donors in the United 
States were reported to range from 0.10-0.34 pg/ml (0.001- 
0.004 |jmol). Some evidence was obtained of a geographic
pattern reflecting established regional differences in the 
selenium levels in crops. Dickson et al (1967) reported
the values of selenium in blood, in Canada, which were similar 
to the above values. From data obtained in New Zealand,
a country with extensive areas of low selenium soil, levels 
of normal New Zealand people were reported as 0.68 pg Se/ml 
(0.009 pmol). Whole blood selenium concentrations are higher 
than plasma or serum concentrations because of the higher 
concentration in the red cell, of the selenoenzyme glutathione 
peroxidase.
4.5.3 Dietary Intake, Absorption and Excretion
The dietary content of selenium is dependent upon the soil 
of the region where plant and animal foodstuffs were originally 
produced. In areas such as North America, dietary intake
is from 50-200 pg/day { 0.63-2.5 pmol/day), whereas in New 
Zealand, where soil selenium is particularly low, diets only 
supply 20-50 pg/day ( 0 .25-0.6 pmol/day ). Fish and other
seafoods are particularly good food sources, as are animal 
liver and kidney. Cereal products* and vegetables' contain
variable amounts due to geographical variation in the soil
content of selenium. The American recommended intake is
50-200 pg (0.6-2.5 pmol/day) selenium. Mixed diets normally 
provide this amount. U.K. surveys do not suggest any generalised 
lack in the average diet.
The role of selenium in human nutrition is complex and 
inter-related with vitamin E, and possibly other "anti-oxidant"
1 2 1
factors. - The chemical form of selenium varies greatly and 
can affect its availability from diet, hence biological action. 
Salts like sodium selenite or selenomethionine are well tolerated.
Comparatively little attention has been paid to the 
intestinal absorption of selenium. About 50% of selenium
from the diet is absorbed by the gut. It is believed from
animal studies that absorbed selenium is at first carried 
mainly in the plasma from which it enters all tissues including 
bone, hair and leukocytes. Selenite, selenium has to undergo
a chemical transformation by the erythrocytes in order to 
bond by the plasma proteins. The process of expulsion of
selenium from the erythrocytes depends upon adequate glutathione 
levels in these cells. Selenium is transported in blood
plasma bound to a variety of proteins, including lipoproteins.
The average plasma concentrations lie in the range 42-190 
pg Se/1 (530-2406 nmol/l). Values depend upon the age of
the population studied as well as recent dietery selenium 
intake.
The main route of selenium excretion is in urine, probably
as organo-selenium complexes, the total amount excreted being
related to current dietary selenium intake. Available human
75 -data shows that 11.2% of the Se, in an intravenous dose
of ( *^^Se)-L-Selenomethionine appeared in the urine five days
after administration, while 2.5% appeared in faeces (Burk 
1976). Measurement of urinary selenium content has long
been used in screening for selenium toxicity by estimating
the urinary output. Values above 100 pg Se/1 (1266 nmol/l) 
are considered as evidence of excessive exposure to selenium.
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4.5.4 Biochemical Importance
The biochemical role of selenium compounds is complex, but 
one important action is as '’antioxidants". A selenoprotein,
glutathione peroxidase is found in most tissues and body 
fluids. This enzyme is a part of the cellular antioxidant 
system, and acting together with the tocophorols (vitamin 
E), protects all membranes, and other intracellular structures, 
from damage by peroxides and other active species generated 
during oxidative metabolism. This is the best known biochemical 
role of selenium.
A further hypothesis has been put forward by Diplock 
(1974); selenium and particularly selenide, is presented 
as having a role in the electron transfer functions associated 
with mitochondria containing non-haem iron proteins.
Also, selenium can be used for modification of heavy 
metal toxicity. The biochemical mechanisms by which selenium 
reduces cadmium and mercury toxicity are unknown, but the 
diminution of metal toxicity by physiological quantities 
of selenium has important implications. These metals are 
becoming more widespread in the environment, so adequate 
selenium nutrition is important to avoid toxicity, particularly 
in animals.
4.5.5 Clinical Effects of Deficiency
Selenium is necessary for growth and fertility in animals 
and for the prevention of various disease conditions which 
show a variable response to vitamin E. These are liver
necrosis in rats and other species, exudative diathesis 
and pancreatic fibrosis in poultry, muscular dystrophy (white 
muscle disease) in lambs, calves and other species, and hepatosis 
dietetica in pigs.
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Human ' evidence of selenium deficiency was previously 
restricted to studies of children suffering from protein 
calorie malnutrition. Addition of extra selenium to an
otherwise adequate diet led to improved weight gain. Recently, 
there has been considerable speculation that suboptimal selenium 
intake may contribute to the incidence of certain forms of 
cancer (Schrauzer 1976) and cardiovascular disease. These
speculations are based on epidemiological data and variables 
other than selenium levels in the soil could be responsible 
for the correlations.
More recently however, symptomatic selenium deficiency 
has been observed in patients fed intravenously using nutrients 
low in selenium (Rijj 1979). One case reported from New
Zealand was of a woman who required long-term intravenous 
feeding following surgery and developed severe muscle pain 
relieved by intravenous supply of selenium as selenium-methionine. 
A patient in America receiving intravenous feeding (Johnson
1981) presented with a cardiomyopathy which was similar to 
that reported in Keshan disease, an endemic condition found 
in areas of China, which has been linked to dietary selenium 
deficiency. Fell et al (1981) reported a patient with biochemical 
signs of selenium depletion, which was corrected by oral 
intake of 2 mg sodium selenite/day (900 pg or 11.3 pmol/day). 
No other biochemical or haematological changes resulted from 
this therapy, nor were there any apparent clinical benefits 
associated with improvement in selenium status.
4.5.6 Biochemical Assessment of Selenium Status
Adequate means of assessing selenium in individuals are needed 
for population surveys and to diagnose selenium deficiency 
(or toxicity). Blood levels of selenium have been widely
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used as an index of selenium status, since the development 
of sensitive fluorometric assays, and atomic absorption spectro­
photometry using a hydride generation system. Plasma or
serum levels of selenium may be a more realistic indicator 
of selenium status, than whole blood selenium. Also, twenty- 
four hour urine determination of selenium is a guide as to the
dietary selenium intake. Furthermore, the activity of selenium 
containing enzyme erythrocyte glutathione peroxidase falls 
in response to a selenium deficient diet and rises with adequate 
selenium intake.
4.5.7 Selenium in Intravenous Nutrition
In hospital practice, the groups of patients at risk of selenium 
deficiency, are those with pre-existing dietary lack, who 
present with extensive malabsorption and gastrointestinal 
disease, severe enough to require supplementary feeding. 
Nutrients commonly used in intravenous feeding are low in 
selenium content. Biochemical evidence of low concentrations 
of selenium in plasma and urine, together with a reduced 
glutathione peroxidase activity, has been found in various 
categories of inflammatory bowel disease (Fell et al 1980).
Since the intestinal absorption of selenium is efficient, 
it is possible to administer sodium selenite or selenomethionine 
orally and 1 mg sodium selenite (450 /ng:5 .7 yumol) per day, 
were suggested as a reasonable therapeutic dosage. However, 
in cases of severe intestinal dysfunction, when oral admin­
istration is not possible, intravenous supply of seleno­
methionine or sodium selenite can be used (Rijj 1981). 
The amount required intravenously has not been determined. 
In this study, 0.4 pmol, that is 32 pg/day of selenium was 
provided intravenously.
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4.5.8 Results of this Study 
Urine Selenium
A) Crystalloid Study
Urine selenium excretion in both groups prior to operation 
was within the normal range (Tables 54 and 55) (632.0 - 560 
pmol/volume ) for the group with additive and (411 - 390.0 nmol/volume 
for the group without additive). When the day prior to
operation was compared with the post-operative days, there 
was no significant rise. Also, when both groups were compared,
on each particular day, there was no significant difference 
between the groups, except on post-operative day 4, when 
there was a significant difference (P less than 0.05). 
The group without additive remained within the lower limit 
of the normal range through the study (Figure 39). At the 
end of the study, in the group with additive, the mean urine 
selenium excretion was (682.0 + 385.0 nmol/volume) and of
nine patients, seven were within the normal range and two 
were above. In the group without additive, urinary excretion 
was (368.0 - 207.0 nmol/volume) and of ten patients, eight
were within the normal range, one was above and one was subnormal. 
In this group, one patient started with subnormal selenium 
concentrations and remained the same through the study.
B) Surgical I.V.N
Prior to infusion, at the beginning of the study, the catabolic 
group started within the normal range (642.0 - 59.0 nmol/volume), 
while the anabolic group was below the normal range (1 0 2 . 0  
- 19.8 nmol/volume) (Tables 56 and 57), After infusion
on days 1-3, the anabolic group came within the lower limit 
of the normal range, and remained the same throughout the 
study (Figure 40), The catabolic group remained constant
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TABLE 54
Selenium in urine. Patients with 4854 Infusion
No. Name Pre-op
Days
Post--op (nmo1 /vol)
1 2 3 4
1 J.B 660 680 640 780 670
2 J.M 440 350 330 350 190
3 S.M 2060 540 660 700 970
4 W.W 463 1798 773 693 1496
5 C.M * * * * *
6 W.A 517 493 . 399 452 549
7 J.S 275 289 296 328 338
8 P.S 288 627 517 381 459
9 W.R 727 2059 1312 744 788
1 0 A.P 262 528 449 699 675
Mean 632 818 597 570 682
S.D 560 644 312 187 385
TABLE 55
Selenium in Urine, Patients without 4854 Infusion
No. Name Pre-op
Days
Post--op (nmo 1 /vol)
1 2 3 4
1 M.M 340 610 2 2 0 380 340
2 A.C 140 330 250 2 2 0 350
3 W.L 420 1 0 0 0 1060 770 450
4 J.M 355 518 660 513 246
5 M.M 233 339 516 194 338
6 H.S 466 577 487 490 8 8 8
7 J.M 1474 501 750 507 293
8 T.C 337 372 410 262 342
9 R.M 173 272 2 2 0 * 361
1 0 H.S 167 305 149 141 76
Mean 411 482 472 386 368
S.D 390 218 288 203 207
* Urine contaminated
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TABLE 56
Selenium in Urine, Surgical I.V.N. Study 
ANABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1-3 8 - 1 0 15-17
1 W.M — 420 480 440 —
2 J.W - 545 - 457 170
3 J.T - 217 - - -
4 I.P 8 8 2 1 1 219 378 -
5 D.M 116 316 264 288 -
6 J.N - - - - -
7 M.K - - - - -
8 M.G - - - — -
9 W.W - 195 207 208 -
1 0 A . G - - - - -
Mean 1 0 2 317 293 354 170
S.D 2 0 141 127 105 -
TABLE 57
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/vol) Mean 1-3 8 - 1 0 15-17
1 A.G 600 505 480 - -
2 A.M - - - - -
3 D.M - - - -■ -
4 H.W - 374 235 297 -
5 I.C 683 838 623 694 290
6 G.R - 946 1 1 1 0 1312 -
Mean 642 6 6 6 632 768 290
S.D 59 270 405 511 -
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during the intravenous feeding period. In ' both groups,
when the day prior to infusion was compared with post-infusion 
days, there was no significant increase. At the end of the 
study, in the anabolic group the mean urinary selenium excretion 
was 354.0 - 105.0 nmol/volume, and all five patients were
within the normal range, while in the catabolic group, the 
excretion was (768,0 - 511.0 nmol/volume),and of three patients,
two were within the normal range and one was above.
C) Medical I.V.N
This group started within the normal range of urine selenium 
excretion (262.0 - 131,0 nmol/volume) (Table 58), On post­
infusion days 1-4 there was a decrease in urine selenium 
excretion which then increased later in the study (Figure
41). At the end of the study, selenium excretion was 213.0
-28.0 nmol/volume and both patients were within the normal
range.
Serum Selenium
A) Crystalloid Study
Both groups prior to operation started within the normal
range (with additive 1526.0 ~ 282.0 nmol/1, and without additive
1070.0 - 398.0 nmol/1) (Tables 59 and 60). Throughout the
study, both groups remained within the normal range (Figure
42). There was a significant difference between the groups 
through the study (P less than 0.05), but in each group,
when the day prior to operation was compared with the post­
operative days, there was no significant increase. At the 
end of the study, on post-operative day 6 , in the group given 
additive the serum selenium concentration was 1539.0 1 283.0
nmol/1 , and of ten patients, seven were within the normal 
range and three were above, while in the group without additive.
TABLE 58
Selenium in Urine, Medical I.V.N. Study
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No. Name Pre-Infusion
(nmol/vol)
Post-Infusion Days
Mean 1-4 9-12 17-20 25-28
1 R.M - 150.0 280.10 - -
2 P.P - 145 127 195 185
3 E.I 393 312 279 349 240
4 J.C 131 170 185 302 -
Mean 262 194 218 282 213
S.D 131 69 65 64 28
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TABLE 59
Selenium in Serum, Patients with 4854 Infusion
No. Name Pre-op Days Post-■op (nmol/1 )
1 3 5 6
1 J.B 1560 1320 1330 1360 1460
2 J.M 1320 1040 1 2 2 0 1300 1360
3 S.M 1320 1390 1650 1710 1870
4 W.W 2040 1750 1800 2030 1990
5 C.M 1610 1250 1320 1420 1620
6 W.A 1393 1089 1304 1418 1456
7 J.S 1279 1013 1114 1241 1203
8 P.S 1170 1190 1340 1440 1470
9 W.R 1683 1595 1633 1392 1823
1 0 A.P 1887 1963 823 823 1140
Mean 1526 1360 1353 1413 1539
S.D 282 318 284 310 283
TABLE 60
Selenium in Serum, Patients without 4854 Infusion
No. Name Pre-op Days Post--op (nmol/1 )
1 3 5 6
1 M.M 1130 1140 1080 1 0 1 0 1 1 1 0
2 A.C 1190 1 0 1 0 1240 1060 1 1 1 0
3 W.L 1620 1390 1420 1550 1490
4 J.M 1600 1270 1330 1340 1370
5 M.M 1050 850 820 850 840
6 H.S 1420 1040 1060 1190 1250
7 J.M 887 1064 1 0 1 0 760 856
8 T.C 595 562 608 747 761
9 R.M 570 469 304 557 545
1 0 H.S 633 508 494 697 722
Mean 1070 930 937 976 1005
S.D 398 323 371 313 308
131
selenium concentration was 1005.0 - 308.0 nmol/1 and of ten
patients, nine were within the normal range and one was subnormal.
B) Surgical I.V.N
Both anabolic and catabolic groups started with a normal
serum selenium concentration. Anabolic group 976.0 - 291.0
nmol/1, and catabolic group 1041.0 - 254.0 nmol/1 (Tables
61 and 62). Both groups remained constant, within the
normal range, throughout the intravenous feeding period. 
After cessation of intravenous selenium, in both groups selenium 
concentration increased (Figure 43). When the groups were 
compared with each other, on each particular day, there was
no significant difference. Also, when the day prior to infusion 
was compared with post-infusion days, there was no significant 
increase. At the end of the study, on days 14-18, the selenium 
concentration in the anabolic group was 903.0 - 286.0 nmol/1,
and all three patients were within the normal range, while 
the serum selenium concentration of the catabolic group was
879.0 - 421.0 nmol/1. Out of four patients, three were within
the normal range and one was subnormal.
C) Medical I.V.N
The patients in this group started below the serum selenium 
normal range (467.0 - 50.0 nmol/1) (Table 63). After the
intravenous feeding on days 1-4, serum selenium concentration
increased steadily to days 14-18, and then there was a decrease 
(Figure 44). The patients were within the lower limit of 
the normal range on days 7-11 and 14-18. At the end of 
the study, two patients were subnormal.
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TABLE 61
Selenium in Serum, Surgical I.V.N. Study 
ANABOLIC GROUP
No. Name Pre-Infusion
(nmol/1 )
Post-Infusion Days
Stopping
ValueMean 1-4 7-11 14-18
1 W.M — 1150 — — 1240
2 J.W 1240 1430 1275 1 2 2 0 1329
3 J.T — 534 622 -
4 I.P 714 615 - 823 -
5 D.M 1216 937 982 - 836
6 J.N - - - - -
7 M.K - - - - -
8 M.G - - - - -
9 W.W 735 735 729 665 940
1 0 A. G - - - - —
Mean 976 900 902 903 1086
S.D 291 343 291 286 236
TABLE 62
CATABOLIC GROUP
No. Name Pre-Infusion Post-Infusion Days
Stopping
Value(nmol/1 ) Mean 1-4 7-11 14-18
1 A . G 1 0 2 0 970 1040 _ —
2 A.M - 925 849 798 -
3 D.M - - - - -
4 H.W 798 659 583 317 -
5 I.C 1304 1152 1228 1160 1215
6 G.R - 570 950 1241 1469
Mean 1041 855 930 879 1342
S.D 254 238 239 421 180
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TABLE 63
Selenium in Serum, Medical I.V.N. Study
No. Name Pre-
Inf
Post-Infusion Days (nmol/I)
Stopping
ValueMean 1-4 7-11 14-18 21-24 28-32
1 R.M 410 410 — 460 - - —
2 P.P - 420 480 700 580 430 -
3 E.I 460 510 490 436 384 403 456
4 J.C 532 - 608 583 - - -
Mean 467 447 526 545 482 417 456
S.D 50 45 58 106 98 14 -
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4.5.9 Discussion 
Selenium Excretion
A) Crystalloid Study
The calculated percentage of urinary selenium excretion was
166.7 -  84.7% of the total infused dose of 1.6 pmol of selenium
over the study period, with no retention of selenium. Urine 
selenium excretion was normal in both groups ; about 200-800 
nmol/day pre-operation. This was not affected either by 
the operation of by extra selenium supplementation.
B ) Surgical and Medical I.V.N
In the surgical group, the anabolic patients had an average 
selenium output of 80.3 - 31.0%, retaining therefore about
2 1 % of the infused dose, whereas the catabolic surgical patients 
excreted about 180.8 - 105.9%, with no retention at all.
Urine selenium excretion was less in medical patients, about
56.4 ~  16.3%, with higher retention than surgical patients,
some 43% of the total infused amount. This is in contrast 
to other patients who show a deterioration in selenium status 
on total parenteral nutrition without supplement. Lane
et al (1981) studied seven intravenous nutrition patients 
for about one month. These patients had inflammatory bowel 
disease or short gut syndrome. In all these patients, they 
found lower serum selenium levels than in normals.
Analyses were performed on specimens from only six patients 
from the anabolic group and four patients from the catabolic 
group for technical reasons.
Serum Selenium
A) Crystalloid Study
Serum selenium was significantly higher throughout the study 
in the group receiving additive. The pre-operative day
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and post-operative day 1 were however, significantly different 
in the two groups, which indicates some pre-existing difference 
in selenium status. Provision of extra supplementation
had no effect on the serum selenium level, which remained 
fairly constant in both groups.
B) Surgical and Medical I.V.N
Serum selenium concentrations were well maintained in the 
surgical anabolic and the catabolic groups throughout the 
intravenous feeding period. Even although the retention
was greater in the medical patients, selenium levels were 
at the lower limit of the normal range.
Conclusions
Selenium behaves differently than other elements such as 
zinc, copper and manganese. These elements show a sharp
decrease after operation as a response to stress, but there 
was no such decrease in selenium concentrations. Also,
no consistent trend was found during the study, to suggest 
the retention of selenium. There were analytical difficulties 
while determining the selenium values. Problems of ventilation 
made the analysis a health risk, since the headaches and 
nausea were experienced, possibly due to the release of volatile 
selenium compounds. Furthermore, no external quality control 
reference material was available for confirmation of the 
urine and serum selenium results. Recently, a technique
using electrothermal atomisation for plasma selenium has 
been adopted, and will be used for future studies.
As far as it can be judged from the different studies,
provision of 0.4 umol (31.58 pg) selenium per day does not
affect pre-existing selenium status. However, none of the 
patients had evidence of clinical deficiency. Therefore,
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no recommendation can be made as to the intravenous supply 
of selenium necessary to prevent or to correct the selenium 
depletion.
Investigations using red cell or plasma glutathione 
peroxidase were also unsatisfactory for technical reasons, 
but should be used for future investigations.
At present, patients with measurable biochemical signs 
of selenium depletion, could be treated with an oral preparation,
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Figure 39
Comparison of selenium excretion in two groups of ten 
patients, with 4854 and without 4854 infusion.
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Figure 42
Comparison of serum selenium concentrations in two
groups of ten patients, with 4854 and without 4854 
infusion.
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Excretion of selenium in ten anabolic patients 
and six catabolic patients receiving 4854 infusion.
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Serum selenium concentrations in ten anabolic patients 
and six catabolic patients receiving 4854 infusion.
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Excretion of selenium in four medical patients receiving 
4854 infusion.
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Serum selenium concentrations in four medical patients 
receiving 4854 infusion.
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CHAPTER 5
5.1 CONCLUSIONS AND RECOMMENDATIONS
It is established that clinically obvious signs of essential 
trace element deficiency can occur during prolonged intravenous 
feeding. This has been recognised worldwide as greater numbers 
of patients are being managed for longer periods by intravenous 
nutrition using purified amino-acid mixtures and energy substrates 
lacking the former "contamination levels" of some trace metals. 
Thus, clinical signs, reversible upon the supply of zinc,
copper, manganese, chromium, selenium and molybdenumi, have 
been reported. Furthermore, as the biological importance
of the fifteen or so essential trace elements in diet are
further understood, it is certain that optimal utilisation 
of the amino-acids, carbohydrate and lipids given intravenously, 
will require the appropriate amount eind appropriate molecular 
species of most of these elements. Complete parenteral
nutrition should aim at providing intravenously the same 
quantity and form of all nutrients present in, and absorbed 
from, the normal diet. Present knowledge does not permit
such an ideal regimen and estimates of requirements have
to be based on empirical evidence, and any proposed intravenous 
therapy must above all be shown to be safe, and free from 
obvious toxic side-effects. Since the "therapeutic index"
of some metals, especially when given intravenously, is low, 
most recommendations are probably cautious, aiming to supply 
the minimal maintenance level to avoid development of gross 
deficiency disease.
The trace metal formation 4854 investigated in this
thesis, was based upon previous clinical and biochemical
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studies of-Addamel^ (Table 2) and the metabolic balance studies 
by Jacobson and Wester (1977). This led to proposals by
Shenkin & Wretlind (1978) for various levels of supply of 
nutrients, including essential trace elements, for different 
categories of patients. Additionally, the recommendations
of the American Medical Association (1979) were considered 
and incorporated. From the studies reported in this thesis, 
it can be stated that:
1) The 4854 mixture is stable and compatible with other intra­
venous fluids, such as saline, glucose, amino-acids and 
lipids.
2) A total of some 559 patient days, in 40 patients, were 
experienced and no instance of toxicity from infusion 
of 4854 was recorded.
3) The retention of the infused metals was clearly better 
when given in saline or glucose rather than with amino- 
acids .
For individual elements, the following can be concluded:
a) Zinc
100 umol (6.54 mg) per day is sufficient for most patients.
This level is in line with the AMA recommendations (2.5-
4,0 mg). The amount supplied in 4854 is significantly more 
than in Addamel^ , which supplied only 20 ^mol (1.31 mg) per 
day, and was clearly unable to maintain zinc status in some 
patients. 1 0 0  jumol zinc per day is a safe dosage and will 
correct mild degrees of zinc deficiency. However, for patients 
with extensive fistula and/or faecal losses, who are receiving 
substantial intravenous energy and amino-acid inputs, increased 
amounts of zinc may be required. Checks upon serum and
urine zinc will give a guide as to the progress of each patient.
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b) Copper
20 umol (1.27 mg) copper per day can maintain serum copper 
levels and will slowly correct a pre-existing copper depletion. 
This level is in line with the AMA recommendations (8-24 
^mol) and is four times the amount in Addamel^ (5 ^mol) which 
was unable to maintain serum copper levels in all patients.
The clinical and haematological consequences of copper 
deficiency in man are much slower to develop than those for 
zinc. However, since an enhanced production of caeruloplasmin 
appears to be a normal response to stress, injury and infection, 
it is important to ensure sufficient copper supply to permit 
increased synthesis of this acute phase reactant. Recently, 
there has been a suggestion that copper deficiency, as with 
zinc deficiency, will impair the immune response, and therefore 
increase the likelihood of infection during recovery.
c) Manganese
Provision of 15 umol (0.82 mg) of manganese per day still 
seems excessive, even although this is much lower than the 
amounts given in Addamel^ (60 yumol; 3.3 mg). The AMA guide­
lines propose 3-13 ^mol/day. Since in the present study,
serum and urine levels of manganese were substantially above 
the reference values, it is proposed that only 7.5 pmol manganese 
(0.41 mg) per day is required. No reports of manganese
R
toxicity have appeared following the widespread use of Addamel , 
confirming the view that manganese is not a particularly 
toxic metal. It is clear that the human requirement for
manganese is very small indeed, and that little convincing 
biochemical or clinical evidence of deficiency has yet been 
published. Nevertheless, provision of some manganese during 
intravenous nutrition would seem justified in view of its
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established biochemical importance.
d) Chromium
Study of this metal continues to be hindered by the lack 
of adequately sensitive and specific methods of analysis. 
However, atomic absorption procedures described in Section 
2 .1 , now allow measurement of normal urine chromium excretion 
and will detect increases in serum chromium reliably. As 
with manganese, human chromium requirements are extremely 
low. Provision of 0.4 ^mol (20.8 mg) chromium per day,
quite definitely increases both serum and urine chromium 
levels well above normal. Also, unavoidable contamination
of amino-acid mixtures during manufacture means that variable 
additional amounts of chromium will be infused. The AMA
recommendation was 0.28-0.38 jumol (15-20 jug) chromium per 
day. It is therefore proposed that only some 0.2 ^mol (10.4 
mg) of chromium should be added to intravenous regimens.
The biochemical importance of chromium is established 
and the clinical effects of severe deficiency are serious. 
Therefore, modest provision of chromium should be made and 
individual patients should be investigated when unexpected 
signs of insulin resistance develop.
e) Selenium
Evidence of the intravenous requirement of selenium has not 
been obtained during this study. Provision of 0.4 ^mol (31,58 
jUg) of selenium per day did not alter selenium levels in 
serum or urine in a consistent manner. No patients were 
studied who had a pre-existing depletion so that it is not 
clear if this level of provision would have corrected biochemical 
abnormalities.
It is proposed to leave the amount supplied at the present
141
value, since this is non-toxic and should supply basal needs. 
For individual patients with severe malabsorptive states 
and biochemical evidence of low serum and urine selenium 
and low glutathione peroxidase activity, a possible option 
is oral provision of sodium selenite which is efficiently 
absorbed from the gut.
Further improvements in selenium assay and the use of 
glutathione peroxidase measurements are required for future 
studies.
Future Investigations
Future study of the amended "4854" mixture is required:
1) Wherever possible, a number of more complete metabolic 
balance studies should be attempted. This will involve 
the assay of metal output in fistula fluid and faeces 
for different categories of patient.
2 )  Direct measurement of metals in tissue, body fluids and 
excreta should be considered along with other appropriate 
"markers" of intracellular biochemical function.
Zinc
Leucocyte zinc levels; liver, muscle and skin biopsy and 
activity of zinc metalloenzymes like thymidine kinase.
Copper
Liver biopsy, copper assay, activity of copper enzymes 
such as red cell superoxide dismutase.
Chromium
Effect of glucose load upon serum and urine chromium levels 
should give an indication of tissue chromium reserves.
Selenium
Systematic study of red cell and plasma GSHPx activity 
will complement direct selenium measurements.
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3) Extension of studies to include the other components of 
4854, namely molybdenum, iodide and fluoride, will depend 
upon the availability of suitable analytical techniques. 
Possible work could include:
a) Iodine
Use of standard thyroid function tests during prolonged 
intravenous nutrition. Interpretation may be difficult
due to changes induced by illness or stress.
b) Fluoride
Direct measurement of serum and urine fluoride using an 
ion selective electrode should be possible. Some study 
of bone biopsy and histopathology might be advisable in 
patients receiving long-term intravenous nutrition, including 
infusions of fluoride.
c) Molybdenum
Direct measurement of serum molybdenum is difficult and 
requires specialist neutron activation techniques. Molybdenum 
excretion is mainly via the urine, probably as the molydate 
anion. Sufficiently sensitive and specific electrothermal 
atomisation and atomic absorption spectrophotometric methods 
may become available. However, indirect estimation of
molybdenum status could be more readily obtained by assay 
of molybdenum dependent enzymes such as xanthine oxidase 
and sulphite oxidase. Additionally, the urinary excretion 
of uric acid and the urinary ratios of sulphate to sulphite 
can be measured.
APPENDIX
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APPENDIX
Patients with 4854 Infusion
No. Name Pre-Op
1
Post-Op
2
Days
3 4 (24 hour urine 
volume/ml)
1 J.B 883 569 1151 2360 2389
2 J.M 1933 815 2047 1927 1204
3 S.M 1093 771 1656 2819 4627
4 W.W 1053 1798 2760 3463 3182
5 C.M * * * * *
6 W.A 1435 1540 2132 1373 2348
7 J.S 736 1383 3111 3317 3677
8 P.S 1 0 2 1 1781 2722 2787 3078
9 W.R 998 2321 2158 2195 1557
1 0 A.P 889 2277 2363 3801 4019
Patients without 4854 Infusion
No, Name Pre-Op Post-Op Days
1 2 3 4 (24 hour urine
volume/ml)
1 M.M 1567 2751 2038 2349 3374
2 A.C 1565 1378 476 384 677
3 W.L 3012 807 1053 3831 4130
4 J.M 1076 720 2868 4273 4092
5 M.M 1793 434 3227 2766 3077
6 H.S 1035 1603 1948 2579 3290
7 J.M 1501 500 1537 1668 1379
8 T.C 1686 2353 3475 3195 1317
9 R.M 642 1024 1179 * 2842
1 0 H.S 1589 839 2915 2312 2723
*Urine contaminated
Patients with 4854 Infusion 
Urine Creatinine
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No, Name Pre-Op Post-Op Days (mmol/volume)
1 2 3 4
1 J.B 18.2 18.8 20.3 19.1 15.8
2 J.M 9.7 8.7 8 . 6 8.9 7.9
3 S.M 10.7 10.3 1 2 . 1 1 0 . 1 1 1 . 6
4 W.W 8 . 0 23.0 15.2 1 2 . 1 1 2 . 1
5 C.M * * * * *
6 W.A 1 1 . 0 12.5 12.4 1 1 . 1 1 0 . 1
7 J.S 15.9 1 0 . 2 1 0 . 6 9.3 9.9
8 P.S 3.8 6.9 6.3 4.2 6.5
9 W.R 10.9 24.4 14.0 10.5 10.9
1 0 A.P 1 0 . 6 14.6 1 1 . 1 11.4 1 0 . 0
Patients without 4854 Infusion
Urine Creatinine
No. Name Pre-Op Post6-0p Days (mmol/volume)
1 2 3 4
1 M.M ■ 8 . 0 13.8 7.1 10.3 1 0 . 8
2 A.C 7.0 15.7 1 2 . 1 11.4 15.9
3 W.L 1 1 . 1 16.5 20.5 14.9 11.7
4 J.M 8 . 1 11.9 15.8 12.4 11.5
5 M.M 12.9 10.3 2 2 . 6 1 0 . 0 12.3
6 H.S 13.4 16.5 15.2 16.0 18.8
7 J.S 22.5 6 . 2 15.7 1 0 . 0 6 . 1
8 T.C 15.0 13.9 13.2 12.5 11.7
9 R.M 9.6 14.3 10.5 * 9.7
1 0 H.S 1 1 . 1 16.4 17.5 1 0 . 6 8.7
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